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A B S T R A C T
Background
Medicines are the most common intervention in most health services. As with all treatments, those taking medicines need sufficient
information: to enable them to take and use the medicines effectively, to understand the potential harms and benefits, and to allow
them to make an informed decision about taking them. Written medicines information, such as a leaflet or provided via the Internet,
is an intervention that may meet these purposes.
Objectives
To assess the effects of providing written information about individual medicines on relevant patient outcomes (knowledge, attitudes,
behaviours and health outcomes) in relation to prescribed and over-the-counter medicines.
Search methods
We searchedMEDLINE, EMBASE,CINAHL,TheCochrane Library, PsycINFO and other databases toMarch 2007. We handsearched
five journals’ tables of contents, and the reference lists of included studies, and contacted experts in the field.
Selection criteria
Randomised controlled trials (RCTs) of medicine users, comparing written medicines information with no written medicines informa-
tion; or trials that compared two or more styles of written medicines information. We only included trials that measured a knowledge,
attitudinal or behavioural outcome. There were no language restrictions.
Data collection and analysis
Two review authors independently extracted data relating to the interventions, methods of the trials, and outcome measures; and
reconciled differences by discussion. Heterogeneity of interventions and outcomes measured meant that data synthesis was not possible.
The results are presented in narrative and tabular format.
Main results
We included25RCTs involving 4788 participants. Six of twelve trials showed thatwritten information significantly improved knowledge
about a medicine, compared with no written information. The inability to combine results means we cannot conclude whether written
information was effective for increasing knowledge. The results for attitudinal and behavioural outcomes were mixed. No studies
showed an adverse effect of medicines information.
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Authors’ conclusions
The combined evidence was not strong enough to say whether written medicines information is effective in changing knowledge,
attitudes and behaviours related to medicine taking. There is some evidence that written information can improve knowledge. The
trials were generally of poor quality, which reduces confidence in the results. Trials examining the effects of written information need to
be better designed and use consistent and validated outcome measures. Trials should evaluate internet-based medicines information. It
is imperative that written medicines information be based on best practice for its information design and content, which could improve
its effectiveness in helping people to use medicines appropriately.
P L A I N L A N G U A G E S U M M A R Y
Written information about individual medicines for patients
Medicines are the most common intervention in most health services. People taking medicines need good quality information: to enable
them to take and use the medicines effectively, to understand the potential harms and benefits, and to allow them to make an informed
decision about taking them. Written medicines information is provided in some countries as a leaflet accompanying medicines, and is
available via the Internet. Our review examined if written information about individual medicines can improve knowledge or attitudes,
or change behaviours relating to taking a medicine.
The findings of this review were inconclusive for a number of reasons. First, because the included trials measured different outcomes in
different ways, we were unable to combine their results. Second, these trials presented the written information for patients in different
ways, and most did not design the leaflets in a way that made them easy to read. Third, in many cases trials were not clearly reported,
so we do not know if they were carried out correctly. Despite these limitations several trials, while using different types of information
and different measures, found written information improved knowledge. This is encouraging for people who want to learn about their
medicines from leaflets. None of the studies showed that written information was harmful.
Future research needs to use improved methods, and needs to examine the same measures on many occasions. It is important that
medicines information be well written and designed to maximise the possibility of improving knowledge. Consumers are increasingly
seeking out health information, including information about medicines, on the internet, but we found no trials examining whether
internet-based medicines information changed people’s knowledge, attitudes, or behaviour.
B A C K G R O U N D
Medicines and medicines information
Medicines are the most common intervention in most health ser-
vices. As with all treatments, those taking medicines need suffi-
cient information: to enable them to take and use the medicines
effectively, to understand the potential harms and benefits, and
to allow them to make an informed decision about taking them
(Raynor 1998).
Evidence-based policy and practice in providing writtenmedicines
information (WMI) for patients is a priority for several impor-
tant reasons. As a European Commission statement (EC 2003)
noted: “People are demanding and using health information on
an unprecedented scale…linked to a change from the individual
as a passive recipient of healthcare and advice, to that of a more
empowered and more proactive consumer of healthcare. The aim
should be to provide a realistic and practical framework for the
provision of information to patients on medicines.”
It is estimated that around half of all patients do not takemedicines
as prescribed (Haynes 2008), leading to wasted resources and sub-
optimal health care. Concern with medicine non-compliance was
themain stimulus in the 1970s and 1980s for research into patient
information needs, and the development of a range of information
materials to meet these needs. The assumption was that simply
increasing patients’ knowledge of treatment would be an effective
means of reducing non-compliance, as evidenced by Ley’s review
(Ley 1988). More recently, an understanding of the complexity of
factors underlying patients’ use of medicines has developed. It is
now recognised that in many cases non-compliance is intentional
rather than the result of ignorance, the inability to recall the in-
formation, or a misunderstanding (RPSGB 1997). It also appears
that self-regulation of medicine-taking by patients is frequently
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not shared with doctors (Lowe 2000). Increasingly, patients are
recognised as active managers of their own health care, and need
to be able to make reasoned decisions about medicine taking in
accordance with wider goals and aspirations (Donovan 1992).
Evidence base and legislation
Along with developments in the understanding of patients’ use of
medicines, legislation and guidelines linked toWMIhave emerged
in the developed world since the 1990s (Raynor 2003). Different
models have been developed, notably in Europe, the US and Aus-
tralia. European Union (EU) legislation introduced in the 1990s
and fully implemented in 1999 requires that a comprehensive
medicines information leaflet for patients be supplied inside the
pack of everymedicine (EC 1992). The leaflets defined by this law
are written and supplied by the manufacturer, according to the
detail of the legislation, and delivered as a package insert. A key
feature of these leaflets is that all information in the Summary of
Product Characteristics (intended for health professionals) must
be included in the patient leaflet, but in a form comprehensible to
the patient. Thus, all warnings, precautions and contra-indications
must be included in the leaflet. The result is often a small, thin,
folded leaflet, dense with information. More recently, studies have
shown that people do not feel that the leaflets meet their needs
(Consumers Assoc 2003; Raynor 2004), and most patients do not
read the leaflet after the first time of being prescribed a medicine
(Raynor 2007a). A subsequent EU Guideline on readability of
the leaflets (EC 1998) included recommendations on describing
the risk of side effects, and what to do about them, which have
since been shown to be ineffective and possibly detrimental (Berry
2002; Berry 2004). Importantly, the Guideline for the first time
recommended testing leaflets with patients.
In Australia, law requires that a manufacturer’s leaflet is available
with all new medicines. A collaborative approach was adopted in
the development of the regulations. The leaflets are computer-gen-
erated in the pharmacy and can run to five pages (Parker 2001).
In the US a voluntary system has prevailed since the 1970s, de-
spite pressure from the Food andDrug Administration (FDA) and
consumers (Nightingale 1995). The leaflets are again computer-
generated, but are, at one page long, generally briefer than those
produced in Australia and Europe. FDA-funded research across
eight US states has given the best overview of any of the national
initiatives (Svarstad 2003). In 1996 the US legislated a target for
the provision of ’useful written information’ to 95% of people
receiving new prescriptions, by 2006 (Congress 1996; Steering
1996).
The legislated format is not the only form of information about
individual medicines available to (and used by) patients (Raynor
1998). Patients may be given additional written information by
health professionals, ormay access it themselves fromother sources
including the internet (Dickinson 2003). Our aim was to in-
clude research on all such sources of information about individual
medicines in the review.
Right to information and concordance
Health policy priorities generally aim to develop higher quality
and more responsive services, where patients’ wishes and auton-
omy are respected (NHS 2000). More pragmatically, they also
aim to increase efficiency and cost-effectiveness. Providing good
quality information about medicines is a prerequisite for informed
consent to treatment. It is also seen to underpin genuine choice of
treatment for patients and active involvement in managing illness.
This characterises the concordant (or partnership) model of med-
ical consultations (RPSGB 1997). Concordance aims to achieve a
shared understanding between the patient and prescriber on treat-
ment choices. Patients may be more likely to take medicines when
they have been actively involved in treatment decisions. However,
there is no evidence that written information alone will increase
compliance in long-term therapy (Raynor 1998). Increased knowl-
edge about medicines may support patients’ decisions not to take
them, as well as to accept them. The goal of concordance is not pri-
marily to increase compliance (though this may be an outcome),
but rather to improve the quality of health care by achieving mu-
tual understanding between patients and prescribers, enabling pa-
tients to take a more active part in decisions about treatment and
illness management when they wish to do so.
A review of existing leaflets revealed many to be medico-centred
and biased toward the biomedical model of illness (Dixon-Woods
2001). Coulter 1999 noted that patients expressed a need for in-
formation about: what was wrong; the justification and outcomes
of tests and treatments; likely illness prognosis; promotion of self
care; awareness of services and self-help support; coping strategies;
informing others; legitimising help seeking; how to access further
information; as well as reassurance. Mental health service users
have expressed the need for information in order to understand
what medicines they are taking and why, how the medicines act,
as well as possible side effects of treatment (Campbell 1998). This
review sought to cover all such eligible research that focuses on
patient outcomes.
New methods of information delivery
The impact of medicines information produced electronically
is starting to be felt. In Australia and the US computer-gen-
erated information in the pharmacy is the mainstay and con-
sumers can also now access both official and unofficial infor-
mation from the internet. In the UK many mandatory leaflets
can be viewed online (at www.emc.vhn.net), and new internet-
based medicine ’leaflets’ called Medicine Guides have been pi-
loted (www.medicines.org.uk). Computer-generated leaflets are
promoted as advantageous in terms of being easily updated, in-
dividualised and made usable for people with special needs. Any
eligible research of electronically generated information about in-
dividual medicines was to be included in this review.
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Secondary research evidence
This review is based on a larger systematic review of the role, value
and effectiveness of WMI for patients which was published as a
Health Technology Assessment (HTA) Report (Raynor 2007b).
A Cochrane review by Haynes and colleagues (Haynes 2008) on
interventions to improve adherence to medication includedWMI
interventions, but only in a much wider context. The reviews
by Buck (Buck 1998) and Koo (Koo 2003) are also relevant to
this topic, but neither examines the effectiveness of information
provision. Over the last 20 years, a number of non-systematic
reviews including policy-related documents (Consumers Assoc
2003; Detmer 2003) have been conducted. Each tends to provide
detailed information about specific aspects of providing written
information about medicines, including the following:
• Psychological approaches (Ley 1988; Wright 1999), impact
on knowledge and compliance (Morris 1979), electronic
generation (Kenny 1998), graphical representation (van der
Waarde 1993), user testing (Sless 2001), information design
(Hartley 1994).
• Particular professional perspectives, such as nursing and
pharmacy (Arthur 1995; Aslani 2000).
• Wider health information (Detmer 2003).
None of this research, however, brings together these separate el-
ements to draw general conclusions about the provision of WMI.
This was the aim of the current review.
O B J E C T I V E S
To assess the effects of providing written information about
prescribed and over-the-counter medicines on patient outcomes
(knowledge, attitudes, behaviours and health outcomes).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs in which the effect of written information
could be compared with a control group or alternative interven-
tion.
In the protocol we stated that the reviewwould includeRCTs in the
first instance, with non-randomised controlled trials, controlled
before and after studies and interrupted time series studies to be
considered in the absence of RCTs. As a number of RCTs were
identified for inclusion, we did not extend the selection criterion
beyond RCTs, since these provide a more robust level of evidence.
Types of participants
We included trials involving patients of any age who had re-
ceived written information about a prescribed or over-the-counter
medicine, including hospital in-patients and out-patients, or those
who received their prescription in primary care. We would also
include trials where patients received their medicine from sources
other than a pharmacy, such as via the internet, since this increas-
ingly reflects trends in provision. Trials were included regardless of
whether or not patients were using a medicine for the first time.
We took care to report the context of each trial, particularly in
relation to patients included or excluded from participation.
Types of interventions
We included trials of interventions using written information
about an individual medicine, such as information contained in a
medicine pack insert or a supplementary leaflet intended for the
medicine user. We would also include non-print written informa-
tion about an individual medicine, such as information contained
on websites. The (often mandatory) information on dosage and
warnings that normally appear on medicine labels were not the
focus of the review.
We excluded trials of:
• interventions where medicines information was not the
main focus of the intervention,
• information provided that aimed to help a patient choose
between two or more medicines,
• information provided to a patient in the form of an
individualised illness management plan, and
• information intended to assist doctors or others to prescribe
medicines.
We slightly revised the approach we had outlined in the protocol
for this review, and instead interpreted ’medicines information’
as information fulfilling at least one of the five European Union
requirements of mandatory leaflets supplied with medicines (EC
2004).
• What the medicine is and how it works,
• Before taking the medicine (contraindications and
precautions),
• How to take the medicine,
• Possible side effects,
• How to store the medicine.
The information might have been given to the patient in isolation,
or as one component of a more complex intervention. However,
for a trial to be included in the review, it had to be possible to
separate the effect of the written information from that of the
other intervention(s).
Throughout the review we use the term ’spoken information’. Tri-
als and other publications in this area variously use the terms ’oral
information’, ’verbal information’ and ’spoken information’ to de-
scribe information communicated other than in a written form.
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The term ’verbal information’ is potentially confusing because it
is used in some WMI research to describe information presented
using words (rather than numbers). In the interest of clarity the
term ’spoken information’ is used throughout this review to de-
scribe information communicated other than in a written form,
and ’verbal information’ to describe the information presented us-
ing words (rather than numbers).
Types of outcome measures
We included four types of outcomes relevant to the provision of a
written information intervention.
Primary outcomes
A change in patient knowledge about the medicine was the out-
come most directly linked to this intervention and was our pri-
mary outcome.
Secondary outcomes
The secondary outcomes were:
• changes in patients’ attitudes towards taking the medicine
(this outcome was added after publication of the protocol),
• changes in patients’ medicine-taking behaviour, and
• changes in patients’ health outcomes. We anticipated that
these were likely to vary considerably according to the setting of
the study, and could include physiological indicators (such as
change in blood pressure) as well as proxy indicators (such as the
number of hospital admissions).
We acknowledge that increased knowledge about the medicine
does not automatically mean the patient is more likely to take the
medicine; indeed an effect in the opposite direction is possible.
The reporting of adverse events was also relevant, given that the
WMI might include information on potential side effects of the
treatment, and this might have an effect on symptom recognition,
classification and reporting by patients.
Search methods for identification of studies
Electronic searches
We searched:
• Cochrane Consumers and Communication Group
Specialised Register (January 1970 to June 2007);
• The Cochrane Library (2007, issue 1);
• MEDLINE (January 1970 to March 2007);
• EMBASE (January 1970 to March 2007);
• CINAHL (January 1982 to March 2007);
• HMIC (January 1979 to March 2007);
• Index to Theses (January 1970 to January 2007);
• ISI Proceedings (January 1970 to March 2007);
• Pharmline (January 1978 to March 2007);
• Proquest Dissertations and Theses (January 1970 to March
2007);
• PsycINFO (January 1970 to March 2007);
• Sociological Abstracts (January 1970 to March 2007);
• Web of Science (January 1970 to March 2007).
Terms from the strategy developed by the Review Group Trials
Search Coordinator for searching the Specialised Register were
used as the basis of an MEDLINE (Ovid) search strategy for the
review, which was amended following publication of the protocol.
Search terms from another review (Forster 2001) were added and a
comprehensive search strategy, using a mixture of thesaurus terms
and keywords, was developed iteratively in MEDLINE. We scru-
tinised the results of preliminary searches and the title, abstract
and MeSH terms from relevant papers were used to improve the
search strategy. We combined the subject search terms with the
Cochrane highly sensitive search strategy phases one and two as
contained in version 4.2.6 of the Cochrane Handbook (Higgins
2006).
We present the MEDLINE (Ovid) search strategy at Appendix 1;
the strategy was adapted for the other databases.
No language restrictions were applied.
Searching other resources
We searched the table of contents (from January 2000 toDecember
2004) of the following journals:
• International Journal of Pharmacy Practice,
• Patient Education and Counseling,
• The Pharmaceutical Journal,
• Social Science & Medicine,
• Sociology of Health & Illness.
We searched the reference lists from included trials and relevant
published reviews to identify further potentially relevant studies.
We contacted experts in the field, and publicised the review in
appropriate journals and at academic conferences.
Data collection and analysis
Selection of studies
One review author (PS) conducted the search and a second author
(DJN) initially screened the studies, by titles and abstracts only for
possible inclusion. The full text versions of all possibly-relevant
studies not excluded at this stage were independently assessed by
two review authors (DJN and PK). Agreement on inclusion of all
studies was reached via consensus.
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Data extraction and management
Two review authors (DJN and PK) independently extracted data
from included studies using a standardised data extraction form,
reconciling differences by discussion. We sought missing data and
clarification of methods and results from study authors, as well as
copies of the written medicines intervention (if it was not pub-
lished). Data were entered into RevMan by one review author
(DJN) and checked by a second review author (PK). When a re-
view author was also author of an included study, the other review
author extracted data with a third party.
Studies were combined according to the difference between the
interventions compared: specifically trials comparing the effect of
WMI against noWMI, and trials comparing the effect of different
ways of providingWMI content.We present a structured narrative
review of the studies.
We had intended to conduct subgroup analyses looking at preven-
tive and treatment medicines, different population groups and the
quality of the information intervention if possible. We had also
intended to assess the quality of theWMI intervention using a val-
idated rating scale, if available, and to conduct sensitivity analyses
based on the intervention quality. These were not possible due to
a lack of comparable studies or data.
Methods of data combination are presented at Appendix 2 for
application in a future update of the review, if possible.
When P values were not reported and the raw data were available,
a Chi2 test of association was conducted, using software data avail-
able from http://www.quantpsy.org. We used the same method
when we aggregated data from studies. For example, in trials with
a 2x2 factorial design with four intervention groups where partici-
pants received both written information or not, and spoken coun-
selling or not; we aggregated over those receiving spoken coun-
selling or not, for the purpose of the analysis. We then recalcu-
lated the P values using the Chi2 test. Aggregation assumes that
there is no interaction between the two variables. In the case of
the two relevant trials, in Peveler 1999 no interaction calculation
is reported, and in Little 1998 the two variables interact on some
of the outcome measures and not on others.
Assessment of methodological quality of included studies
We assessed methodological quality in accordance with the
Cochrane Handbook (Higgins 2006). The extent of concealment
of randomisation (allocation) was the key methodological quality
assessment, since this has been shown to influence the reported
size of treatment effect (Schulz 1995) and is likely to be relevant
to trials of information provision. We reported whether trials ad-
equately concealed allocation, for example by using third party
randomisation. If concealment was not adequate, we noted if the
method was inadequate; was not clearly reported; or if randomi-
sation was not concealed.
Another key issue in assessing trial quality, that ofmasked outcome
assessment, was less relevant to this area of research since patient
and assessor masking are both difficult to achieve for the provision
of written information. We recorded if the outcome assessor was
masked.
Consumer participation
The Cochrane Consumers and Communication Review Group’s
editorial process for the protocol involved two anonymous con-
sumer referees, one from Australia and one from the United King-
dom. A further two consumer referees were included in the edito-
rial process for the full review.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The searches produced 13,613 references, of which 13,466 were
excludedby their title or abstract alone.Weobtained the remaining
147 papers in full text, of which 122 studies were rejected. For
reasons, see Characteristics of excluded studies.
We included trials that compared ’spoken information’ alone
against ’spoken information combined with written information’.
We excluded trials that compared ’no information’ with ’written
information plus spoken information’, because it was not possible
to determine the effects of written information alone.
Included studies
We included 25 trials. The trials were conducted in nine countries:
eight in the USA; eight in theUK; two in Belgium; two in Canada;
and one each in Finland, France, Hong Kong, Switzerland and
Turkey. The earliest trial was published in 1972 (Clark 1972), and
the most recent in 2004 (Knapp 2004).
Participants
The 25 included trials enrolled 4788 participants; ranging from
34 (Johnson 1986) to 719 (Gibbs 1989). All participants were
currently taking amedicine, (an inclusion criterion of this review).
The overall mean age of participants, reported in 17 trials, was 43
years (16 to 88 years). In the 20 trials which reported the sex of
the participants, 34% weremen. Little 1998 enrolled only women
(636), as it examined the effects of information about a contra-
ceptive medicine. Excluding Little 1998 the overall proportion of
men enrolled in the trials rises to 41%. Two trials reported the
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ethnic background of participants (Morris 1982; Vander Stichele
1992). Of the 333 participants in these two trials, 69% were from
a non-white ethnic group. However, none of the participants in
the trial of Vander Stichele 1992 were from a non-white group.
Most trials were poorly reported; the reason participants were of-
fered particular medications could not always be ascertained.
Trial categorisation
We categorised the trials by their experimental intervention and
comparison:
1. WMI compared to no WMI: this included trials of WMI
versus no intervention, and WMI and spoken information versus
spoken information alone.
2. Presentation of WMI: this included trials of WMI versus
WMI, and trials comparing ways of providing risk descriptor
information.
Information content
The content of the written information provided in the trials was
matched to the five content categories of information mandated
in the EU (see Background). Eighteen of the 25 trials (72%) pub-
lished a full or partial copy of theWMI intervention (or later pro-
vided one on request), which allowed content analysis. In seven
studies, few details of the intervention or its delivery were pro-
vided, making problematic the assessment of intervention quality.
We noted a considerable amount of heterogeneity in content of the
WMI; most interventions, however, included information about
’What thismedicine is andwhat it is used for?’ (19 trials); and ’Pos-
sible side effects’ (19 trials). Six trials provided information per-
taining to all five EU categories (Gibbs 1989; Peveler 1999; Regner
1987; van Haecht 1991; Vander Stichele 1992; Vesco 1990).
Ten trials reported a theory or evidence base as the rationale for
the design of the intervention. Four trials reported a theoretical
basis to their design features and content:
• Bergus 2002 (information-order effect);
• Dodds 1986 (recommendations of Drugs and Therapeutic
Bulletin 1981);
• Dolinsky 1983 (theory of read-organise-attend); and
• Baker 1991 (Plain English Campaign involvement in WMI
design, not referenced).
Six trials used evidence-based decision features and content:
• Gibbs 1989 (intervention had been previously piloted,
George 1983; Gibbs 1987);
• Desponds 1982 (based on the findings of two research
papers, Bellantuono 1980; Greenblatt 1978);
• Labor 1995 (revised after a pilot study, and using Flesch
reading levels test (Flesch 1948));
• Arthur 1998 (used Flesch reading levels test, Flesch 1948);
• Strydom 2001a (intervention previously piloted, Strydom
2001b); and
• Clark 1972 (intervention based on results of a
questionnaire, not referenced).
Nineteen studies involved WMI for chronic conditions (Arthur
1998; Baker 1991; Bergus 2002;Clark1972;Gibbs 1989; Johnson
1986; Knapp 2004; Kumana 1988; Little 1998; McBean 1982;
Morris 1982: Peveler 1999; Pope 1998; Regner 1987; Robinson
1986; Savas 2001: Strydom 2001a; Vander Stichele 1992; Vesco
1990). This included:
• Five trials that provided information about NSAIDs
(Arthur 1998; Gibbs 1989; Pope 1998; Savas 2001; van Haecht
1991); and
• Ten trials that provided information about a cardiovascular
medicine (Baker 1991; Clark 1972; Dolinsky 1983; Gibbs 1989;
Johnson 1986; Knapp 2004; McBean 1982; Morris 1982;
Regner 1987; Vander Stichele 1992).
Five studies providedWMI for acute conditions (Desponds 1982;
Dodds 1986; Labor 1995; Peura 1993; van Haecht 1991); and
one for both chronic and acute conditions (Dolinsky 1983).
Four trials provided information about a medicine for treating
mental health problems (Desponds 1982; Peveler 1999; Robinson
1986; Strydom 2001a) and three for antibiotics (Dodds 1986;
Dolinsky 1983; Peura 1993). Four trials provided information
about medicines not within these classes (Bergus 2002; Kumana
1988; Labor 1995; Little 1998). Five trials (Dolinsky 1983; Gibbs
1989; Johnson 1986; McBean 1982; Vander Stichele 1992) pro-
vided information for more than one medicine.
Eleven studies involved WMI for multiple medications (Arthur
1998; Baker 1991; Desponds 1982; Dodds 1986; Dolinsky 1983;
Dolinsky 1983; Knapp 2004; Peura 1993; Peveler 1999; Strydom
2001a; Vander Stichele 1992) and 13 studies involved WMI for
single medications (Bergus 2002; Clark 1972; Johnson 1986;
Kumana 1988; Labor 1995; Little 1998; McBean 1982; Morris
1982: Pope 1998; Regner 1987; Savas 2001: van Haecht 1991;
Vesco 1990). In one study the number of medications was unclear
although it appeared to be for multiple medications for treating
mental health problems (Robinson 1986).
Risk of bias in included studies
Many included studies did not report clearly how they were con-
ducted,making it difficult to assess their quality. Ten trials reported
adequate randomisation (Arthur 1998; Bergus 2002;Knapp2004;
Little 1998; Peveler 1999; Pope 1998; Savas 2001; Strydom2001a;
van Haecht 1991; Vander Stichele 1992), while 15 trials either
failed to report their randomisation method, or reported it in an
unclear manner.
Eight trials reported how they attempted to conceal allocation,
but only five of these (Arthur 1998; Desponds 1982; Little 1998;
Peveler 1999; Strydom 2001a) were judged to have done so ade-
quately (using either remote access or coded/numbered envelopes).
Therefore the other three trials (Johnson 1986; Knapp 2004; Pope
7Written information about individual medicines for consumers (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1998) were judged to have inadequately concealed the allocation
process. The remaining 17 trials did not clearly report how they
had concealed allocation.
Ten trials described an adequate method for blinding the out-
come assessment (Desponds 1982; Johnson 1986; Kumana 1988;
Labor 1995; Little 1998;McBean 1982; Peveler 1999; Pope 1998;
Strydom 2001a; van Haecht 1991); two trials reported a method
which was inadequate (Dodds 1986; Knapp 2004).
Twenty two trials reported loss to follow-up (Arthur 1998; Baker
1991; Clark 1972; Desponds 1982; Dodds 1986; Dolinsky 1983;
Knapp 2004; Kumana 1988; Labor 1995; Little 1998; McBean
1982;Morris 1982; Peura 1993; Peveler 1999; Pope 1998; Regner
1987; Robinson 1986; Savas 2001; Strydom 2001a; van Haecht
1991; Vander Stichele 1992; Vesco 1990). This ranged from none
(Desponds 1982;Dolinsky 1983;Knapp2004) to 68%(Robinson
1986). Mean loss to follow-up in the 22 trials reporting it was
16%. Loss to follow-up is defined as outcome measurement being
unavailable or incomplete at the final data collection for each trial.
Eleven trials clearly reported when participants withdrew (Arthur
1998; Clark 1972; Desponds 1982; Dodds 1986; Dolinsky 1983;
Knapp 2004; Labor 1995; Savas 2001; Strydom 2001a; Vander
Stichele 1992; Vesco 1990). Withdrawal rates ranged from none
(Clark 1972; Desponds 1982; Dolinsky 1983; Knapp 2004) to
37% (Labor 1995). Mean withdrawal in these eleven trials was
12%. Withdrawal is defined as non-receipt or partial non-receipt
of the intervention after randomised allocation.
Effects of interventions
Outcome data are presented in Table 1.
There was extensive heterogeneity in the design and conduct of
the 25 included trials, and the outcomes measured; therefore a
statistical synthesis was not possible. Measures of knowledge and
satisfactionwere often developed for individual trials and appeared
to measure different components of these outcomes. Some studies
reported few details of the intervention or its delivery, making
problematic an assessment of intervention quality. We present a
structured narrative and tabular review of the study results.
Twenty trials compared WMI to no WMI, and eight trials com-
pared different types of WMI presentation.
No studies showed an adverse effect from WMI.
Written medicine information versus no written medicine
information
Twenty trials compared the effect of providingWMIwith noWMI
(Arthur 1998; Baker 1991; Clark 1972; Dodds 1986; Dolinsky
1983; Gibbs 1989; Johnson 1986; Kumana 1988; Little 1998;
McBean 1982; Morris 1982; Peura 1993; Peveler 1999; Pope
1998; Regner 1987; Robinson 1986; Savas 2001; Strydom 2001a;
Vander Stichele 1992; Vesco 1990). Little 1998 compared two
different WMI interventions with a blank leaflet. Clark 1972 and
Dolinsky 1983 each compared the effects of two different WMI
interventions with no written or spoken information. We report
the comparison of the two WMI formats for each of these three
studies (Clark 1972; Dolinsky 1983; Little 1998) below.
Of the 20 trials comparing the effect of providing WMI with no
WMI, 12 trials compared WMI against no information (Clark
1972; Dodds 1986; Dolinsky 1983; Gibbs 1989; Johnson 1986;
Kumana 1988; Little 1998; McBean 1982; Morris 1982; Peveler
1999; Vander Stichele 1992; Vesco 1990). The other eight trials
gave both groups in the trial (those receiving and those not receiv-
ing WMI), additional spoken information (Arthur 1998; Baker
1991; Peura 1993; Pope 1998; Regner 1987; Robinson 1986;
Savas 2001; Strydom 2001a).
Seventeen of the 20 trials in this broad category measured a change
in knowledge (Arthur 1998; Baker 1991; Clark 1972; Dodds
1986; Dolinsky 1983; Gibbs 1989; Johnson 1986; Kumana 1988;
Little 1998; McBean 1982; Morris 1982; Peura 1993; Pope 1998;
Regner 1987; Robinson 1986; Savas 2001; Strydom 2001a);
three a change in attitudes (Baker 1991; Gibbs 1989; McBean
1982); and eight a behavioural outcome (Dodds 1986; Dolinsky
1983;McBean 1982;Morris 1982; Peveler 1999; Robinson 1986;
Vander Stichele 1992; Vesco 1990). Seven trials (Baker 1991;
Dodds 1986; Dolinsky 1983; Gibbs 1989; McBean 1982; Morris
1982; Robinson 1986) measured more than one type of outcome.
No trials measured a health outcome.
Knowledge
Most of the studies measuring knowledge did so in a way that was
unique to that trial (see table Characteristics of included studies).
Findings were mixed, although most studies measuring knowl-
edge found that either the WMI intervention increased knowl-
edge, including recall of the information and recall of side effects,
or made no difference. Twelve trials examined the effect of WMI
compared to no information on knowledge: six found a statisti-
cally significant effect favouring WMI (Arthur 1998; Clark 1972;
Johnson 1986; Little 1998; Robinson 1986; Savas 2001); three tri-
als (Kumana 1988; McBean 1982; Strydom 2001a) did not. The
three remaining trials (Dolinsky 1983; Gibbs 1989; Pope 1998)
found a mixture of significant and non significant results. In the
trial by Gibbs 1989, more participants receiving written informa-
tion gave the correct answer to questions about the medicine, for
four of nine questions. Significantly more people who received no
WMI knew the name of the medicine compared to those who
receivedWMI. (These results were statistically significant). Partic-
ipants receiving WMI had significantly greater awareness of side
effects (aggregated over all study drugs) than those receiving noth-
ing. In the trial by Pope 1998, two of 11 knowledge outcomes
were statistically significant: one favouring the written informa-
tion, and one favouring the control. The trial by Dolinsky 1983
reported no significant difference in correct recognition of the two
study drugs between those given one of two WMI interventions
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and those receiving no intervention, but did not report individual
statistical comparisons between groups.
We further sub-categorised the trialsmeasuring knowledge accord-
ing to the particular types of knowledge they assessed.
Recall of information about the medicine
Four trials examined participants’ recall of the information they
were given about the medicine (Baker 1991; Dodds 1986; Little
1998; Peura 1993). The trial by Dodds 1986 found significantly
higher recall among those given WMI compared with those who
were not. Two studies found a significant difference for only half
of the questions asked (Baker 1991; Peura 1993). Little 1998 used
a factorial design to compare the effectiveness of an experimental
evidence-based summary leaflet, a standard leaflet and no leaflet,
on women’s knowledge of an oral contraceptive. This was in addi-
tion to an assessment of the effect of questioning by their doctor
or nurse. Outcomes (measured by a validated questionnaire) were
aggregated by whether or not the participants were questioned.
The trial reported that recall was greater for patients given the
‘summary leaflet’ (33%) than those given no WMI (19%), (P <
0.05). However, patients given the full Family Planning Associa-
tion leaflet did not have better recall than the no WMI group.
Recall of side effects
Six trials measured knowledge about side effects (Baker 1991;
Gibbs 1989;Morris 1982; Peura 1993; Pope 1998; Regner 1987).
Four of these trials found that patients given WMI had higher
knowledge of side effects compared with those given no WMI;
these resultswere statistically significant in three trials (Baker 1991;
Peura 1993; Regner 1987). Morris 1982 found that the group
given WMI were able to name more side effects at follow-up, but
also namedmore incorrect side effects than the control group.Tests
for statistical significant were not reported by this study, and there
was not enough data reported to calculate P value. In contrast,
Pope 1998 found that patients given the information sheet/leaflet
listed fewer side effects (P = 0.02), although the number of correct
side effects listed was not statistically significant between the two
groups (P = 0.09).
Attitudes
Three trials comparing the provision of WMI with no WMI as-
sessed participants’ attitudes towards the information given; specif-
ically whether or not they felt satisfied with the information pro-
vided (Baker 1991; Gibbs 1989; McBean 1982).
Baker 1991 examined participants’ attitudes regarding the useful-
ness and ease of comprehension of theWMI (both groups received
spoken information, with one group receiving additional WMI).
Significantly more participants receiving the WMI felt it was easy
to understand (84%) compared with those receiving only spo-
ken information (33%). There was also a significant difference in
perceptions of the information’s usefulness: 84% receiving WMI
thought it was useful or extremely useful, compared with 33%
of those in the control group (P < 0.001). Additionally, signifi-
cantly more people receiving WMI felt that they had been given
sufficient information (74%) compared with those in the control
group (14%; P < 0.001).
Baker 1991 also examined whether the provision of WMI in addi-
tion to spoken information reduced worry about drug treatment,
and found a statistically significant effect: 53% of those given ad-
ditional WMI reported less worry, compared to 25% in the con-
trol group (P < 0.05). Participants given noWMIwere more likely
to feel that information about medicines given to them could be
improved: 64% compared with 27% among those who had been
given WMI (P < 0.001). Similarly Gibbs 1989 and McBean 1982
reported that participants given WMI expressed greater satisfac-
tion with the information provided. This difference was statisti-
cally significant in the trial by Gibbs 1989. McBean 1982 did not
test for significance.
Behaviour
Eight trials assessed the effects on behaviour of providing WMI
versus not providingWMI (Dodds 1986;Dolinsky 1983;McBean
1982;Morris 1982; Peveler 1999;Robinson 1986;Vander Stichele
1992; Vesco 1990). Six trials examined compliance with the
medicines’ instructions: compliance was found to be higher among
people given WMI. However no difference was found when bi-
ological markers were used to assess compliance. Three studies
found that compliance was greater for those who had received
WMI (Dodds 1986; McBean 1982; Robinson 1986), although
one of these studies did not report statistical tests (McBean 1982).
There was no difference in compliance between the groups in
one trial (Vander Stichele 1992). McBean 1982 and Dodds 1986
performed a tablet count; but Dodds 1986 also interviewed pa-
tients. Vander Stichele 1992 used a monitored dose system; while
Robinson 1986 measured compliance as rated by the psychiatrists
(based on a combination of patient report; tablet count; and clin-
ical judgement).
Morris 1982 examined the mean number of health problems re-
ported by participants. They found that the group given WMI
reported on average slightly more side effects at follow-up: 4.1 out
of a possible 17, compared to 3.6 out of 17 for the control group.
Tests for statistical significant were not reported by this study,
and there was not enough data reported to calculate a P value. In
the trial by Peveler 1999 we aggregated the effect of information
against none by combining the groups receiving counseling or no
counseling. No difference was found in the self-reported contin-
uation of the medication for those receiving written information,
and those receiving none. Vesco 1990 confirmed compliance - or
adherence to the treatment regime - through assayed blood levels,
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and found no difference between those given WMI and those not
given it, although this result was not significant. The study also
found no significant differences between intervention and control
groups in the proportion who stopped taking their medication,
but did find that significantly more people in the WMI group
reported a side effect (P < 0.05).
The trial by Dolinsky 1983 reported no significant difference in
correct application of information about the two study drugs be-
tween those given one of two WMI interventions and those re-
ceiving no intervention, but did not report individual statistical
comparisons between groups.
Written medicine information presentation
Eight trials compared the effects of presenting WMI in different
ways (Bergus 2002; Clark 1972; Desponds 1982; Dolinsky 1983;
Knapp 2004; Labor 1995; Little 1998; van Haecht 1991). Five
of these trials measured knowledge (Clark 1972; Desponds 1982;
Dolinsky 1983; Knapp 2004; Little 1998), four an attitudinal
outcome (Bergus 2002; Desponds 1982; Knapp 2004; Labor
1995), and two behaviour change (Dolinsky 1983; van Haecht
1991). We found no trials measuring a health outcome.
Knowledge
Themajority of the five trials comparing different ways of present-
ing WMI used heterogeneous outcomes to measure ’knowledge’.
Findings were mixed, although most studies found the interven-
tion either improved knowledge or made no significant difference.
Clark 1972 found that programmed instruction significantly in-
creased understanding of the use of the drug, compared with the
standard format handout (P = 0.008).
Desponds 1982 also used a factorial design to compare the effect
of an experimental leaflet with the manufacturer’s leaflet, for each
of four anxiety medications. More participants given the experi-
mental leaflet answered the questions correctly (47%), compared
to those receiving the manufacturers’ leaflet (38%), but no sta-
tistical tests were performed to determine whether the result was
significant.
Dolinsky 1983 found no significant difference in correct recogni-
tion of the two study drugs between those givenWMI in a ’read-or-
ganise-attend’ format or those given an easy-to-read format (’read-
able’ information) or those given no intervention, but individual
statistical comparisons between groups were not reported.
Knapp 2004 found that providing information of the risk of side
effects as a numerical description was significantly more effective
in helping people make a correct estimation of risk than giving the
same information as a written verbal description (see Table 1).
Little 1998 foundmorewomenwhowere given the evidence-based
summary leaflet correctly answered all questions (33%) compared
with those given the standard leaflet (24%), but this difference
was not statistically significant.
Attitudes
Four trials comparing different ways of presentingWMImeasured
attitudinal outcomes (Bergus 2002;Desponds 1982; Knapp 2004;
Labor 1995). The findings showed the experimental WMI had
a significant effect on attitude, although these outcomes varied
between trials.
Two trials (Bergus 2002; Knapp 2004) examined whether pre-
senting theWMI in different ways affected participants’ decisions
to take the medicine. Bergus 2002 found that the order in which
people were given information about the benefits of a medication
and the likelihood of side effects affected ratings of favourability of
treatment; they were significantly less favourable when informa-
tion about the risks was given after information about the benefits
(P = 0.02). Knapp 2004 examined participants’ satisfaction with
side effects risk descriptor information, which was provided nu-
merically or verbally. People who had read the verbal information
were more likely to say it would have an effect on their decision to
take the medicine, and this difference was statistically significant
for one of two side effects (constipation; P < 0.05).
Knapp 2004 also found that people who received numerical risk
information reported being more satisfied with the information
than those receiving verbal information; this difference was sta-
tistically significant for one of two side effects (pancreatitis; P <
0.05).
Labor 1995 examined the effect of five leaflets that varied in terms
of wording and the amount of information included. Significantly
more participants given WMI with ’normal’ wording judged the
length to be ’about right’ (P < 0.0001) and the complexity to
be ’about right’ (P < 0.0001), compared with those given other
formats. Participants given information worded for professionals
were more critical of it than those who received simple or normally
worded information (P = 0.24). Participants given simply worded
information judged it to be more useful than any other group (P
= 0.19).
Desponds 1982 found that participants receiving the experimental
information more often reported feeling the text to be easy to
understand (P < 0.01), complete (P < 0.05) and to have a lot of
new information (P < 0.05). The differences between participants’
views of the experimental and standard information on being ’easy
to read’ or ’interesting’ were not statistically significant.
Behaviour
Two trials examined aspects of behaviour, and neither found a sig-
nificant effect of one WMI over another. Dolinsky 1983 found no
significant difference in the correct application of the two study
drugs between those givenWMI in a ’read-organise-attend’ format
or those given an easy-to-read format (’readable’ information) or
those given no intervention, but individual statistical comparisons
between groups were not reported. vanHaecht 1991 found no sta-
tistical difference in the proportion of people that reported reading
a leaflet thoroughly when an experimental leaflet with improved
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readability and layout was compared with a traditional insert (P =
0.15).
D I S C U S S I O N
Summary of main results
Most of the 25 studies included in this review did not report their
methods clearly; and where reporting was transparent, we often
judged that the studies had not been conducted in such a way as to
reduce bias. Several studies did not conduct statistical tests on the
study results, and there was considerable heterogeneity in terms of
the types of WMI interventions used and the outcomes measured.
These are not necessarily barriers to meta-analysis as some het-
erogeneity between interventions is inevitable. The heterogeneity
of outcome measures was large however, which negated the pos-
sibility of a meta-analysis. We could not combine the results of
trials to determine if WMI was effective in changing knowledge,
attitudes or behaviour related to medicine taking. Furthermore, a
number of recent trials were not included in this review because
they assessed condition-based information, rather thanmedicines-
based information, and therefore did not meet the inclusion cri-
teria. We found no trials that evaluated the effects of WMI on
health outcomes. Despite systematic searching, we were not able
to identify relevant trials published later than 2004 for inclusion.
We would welcome information on trials that we may have inad-
vertently missed.
Some individual trials showed improved knowledge about a
medicine for people receiving WMI compared to those who did
not. For example, the trials measuring recall of information (Baker
1991; Dodds 1986; Little 1998; Peura 1993) tended to favour the
provision of written information, as did those measuring recall of
side effects (Baker 1991; Gibbs 1989; Morris 1982; Peura 1993;
Pope 1998; Regner 1987). In around half of the trials these results
were statistically significant.
To determine whether one way of presenting WMI was more ef-
fective than another, we evaluated trials that compared different
ways of presenting information. Again the evidence was inconclu-
sive. One trial examining understanding of the risk of side effects
found that written information provided numerically was signifi-
cantly more effective than written information provided verbally
(Knapp 2004). This is consistent with the findings of a series of
trials that evaluated risk descriptor information in hypothetical
scenarios using homogenous interventions and outcome measures
(for example Berry 2002a; Berry 2004). These trials were not el-
igible for inclusion in this review, but were included in the UK
Health Technology Assessment (HTA) report (Raynor 2007b),
which found, contrary to EU guidance, that giving information
about the risk of a side effect as a numerical descriptor was more
effective than a verbal risk descriptor for improving people’s un-
derstanding of the risk.
Knapp 2004 also found that providing information about the
risk of a side effect numerically can significantly affect people’s
attitudes to taking amedicine.However, the overall evidence of the
impact of WMI on attitudes was unclear. In addition, the general
difficulty in quantifying an attitude (Littlewood 2005) can cast
some doubt on the validity of several trials which used this as an
outcome measure.
Five of the six trialsmeasuring compliance found that the provision
of WMI helped to achieve compliance, but the results were sig-
nificant for only two trials (Dodds 1986; Robinson 1986). Dodds
1986 relied on self-reported compliance with antibiotic treatment
over three to five days. Robinson 1986 measured follow-up of un-
named drugs for treating mental health problems for a fortnight
only. It is debatable whether these findings of compliance relating
to short-term medicine use can be generalised to more chronic
conditions. Overall there was no strong evidence that providing
WMI on its own will improve adherence to medicine instructions.
Furthermore, it is important to recognise that an informed deci-
sion may lead someone not to take a medicine (Raynor 2007b).
Wehoped to examine the effects of internet-basedmedicines infor-
mation, but found no trials evaluating this form ofWMI. Users of
medicines have expressed the need for evaluation of internet-based
medicines information (Raynor 2007b) and the lack of studies of
WMI provided on the internet identifies a gap between the themes
examined in reviews of medicines information and the needs of
users (Nicolson 2006). This evidence gap highlights the need to
put the evaluation of internet-based medicines information firmly
on the research agenda (Nicolson 2007).
Overall completeness and applicability of
evidence
Because of the large degree of heterogeneity in the design of the in-
terventions, the outcomes chosen and the way the outcomes were
measured, we were unable to perform a meta-analysis. For exam-
ple, comparing theWMI to the EU categorization, we noted wide
differences in the specific content presented. This examinationwas
further hampered by a number of papers not providing a copy of
the intervention, or not adequately describing the intervention.
The outcomes measured differed widely, and when trials reported
the same outcome (e.g. knowledge), this was often done using a
trial-specific tool. In addition to these problems, we found several
trials lacked statistical tests, and provided insufficient information
to enable us to perform these. Our inability to conduct a meta-
analysis meant that we were unable to undertake sub-group analy-
ses, or test for heterogeneity of the results. Future trials should use
common outcomes (perhaps using standardised measures), so as
to enable a quantitative synthesis. Furthermore the evaluation of
interventions containing medicines information under standard
headings or criteria would also enable a quantitative synthesis.
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The overall mean age of the participants in the trials reporting
age was 43 years, yet most people who take medicines long-term,
and so perhaps have the greatest need for effective information,
will be older. This suggests that study participants may not be
representative of the target audience of WMI.
Some older trials in the review, particularly those comparingWMI
with no WMI, might be seen as less relevant in the context of
current health care. Patients can now access information about
medicines and other aspects of health care on the internet, and so
trials including comparison groups given no WMI are likely to be
less convincing. The evaluation of WMI by trials therefore neces-
sarily reflects the regulatory context that determines its provision.
For example, in the USA, Japan, Australia, Israel, and in the EU,
there are specific laws that govern the use of WMI. This presents
a challenge for research: EU legislation means that research eval-
uating the effects of WMI compared with no WMI is no longer
possible. Instead research compares the impact of presentingWMI
in different formats, to evaluate their relative effectiveness. Future
versions of this review will contain more trials comparing the ef-
fect of two or more formats of WMI, and it is likely that the num-
ber of included trials examining the relative effect of WMI will
eventually outnumber the trials examining the absolute effect (i.e.
WMI vs. nothing).
We also found it rare for information in the included trials to be
provided in accordance with all five EU medicines information
categories; only six trials provided information reflecting all five
categories. The evidence has therefore largely been derived from
trials examining interventions that do not reflect current standards
for WMI (in the EU); for example most trials did not provide
information relevant to ’before taking the medicine’ or ’how to
store it’. This can again be considered an historical effect, as many
of the trials were conducted before this legislation was enacted.
Enabling medicine users to be involved in making an informed
choice about taking their medicines is a fundamental principle
of concordance (also known as ’partnership in medicine taking’),
and promoted in policy documents across many countries; for
example in the EU by EC 1992. It is disappointing then that there
is no clear evidence to show the effectiveness ofWMI for changing
knowledge, attitudes and behaviours relating to medicine taking.
Quality of the evidence
The conduct of the trials as a whole was poor, and this casts doubt
on their results. For example only ten trials confirmed adequate
blinding of the outcome assessor. Furthermore, at least three trials
inadequately concealed the allocation sequence (and a further 17
trials did not report how this was conducted). Inadequate conceal-
ment is the greatest source of overestimation of treatment effects
(Juni 2001), therefore doubt may be cast on the validity of the
results of these trials.
The poor quality of many of the included trials has limited our
capacity to provide a conclusive answer to the research question.
One explanation is that this represents an historical effect, as most
studies were conducted before the CONSORT statement, when
there was less consensus on what constituted best practice in trial
conduct.
Agreements and disagreements with other
studies or reviews
There are few systematic reviews relevant to the area of medicine
information for consumers, with which to compare our findings.
Haynes 2008 evaluated interventions to help patients follow pre-
scriptions for medicines. Of the 78 trials they included, 18 ex-
amined the provision of verbal, written, or visual material for pa-
tients. Of these, we included one which met our inclusion crite-
ria: Peveler 1999. Haynes 2008 was able to distinguish between
the short-term and long-term effectiveness of different methods
to improve adherence to medications; whereas we were unable to
determine if written information is effective per se.
Our review is one component of a wider review of the role, value
and effectiveness of WMI (Raynor 2007b). This review found
medicine users do not value WMI as it is currently provided, and
a key element in providing effectiveWMI is the application of the
principles of plain writing and information design. Leaflets that
are well written and designed, with a sound theoretical basis for
their wording and design, stand a better chance of getting their
message across effectively. Research is needed to determine how
far information derived from these principles affects knowledge
and attitudes. To date this has been the exception rather than the
norm; more than half the trials included in our review had no
explicit theoretical or evidence base for the design and content of
the medicines information. Essentially these studies examined a
stimulus-response relationship; they can show an association, but
cannot explain why the design of the information was effective or
not. The importance of appropriate wording and design ofWMI is
acknowledged by European legislation which stipulated that from
2005 medicines information had to be tested on target groups to
ensure legibility, clarity, and ease-of-use (EC 2001). This paved
the way for the usability testing of all medicine information leaflets
(EC 2004), which affects the design and provision of WMI, as
well as how subsequent research will evaluate WMI.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
WMI should be available, not only because of legislation, but be-
cause this reviewhas found evidence, albeit frompoorly conducted
studies, to show that it may improve knowledge of the medicine.
Furthermore, no studies showed an adverse effect from WMI.
12Written information about individual medicines for consumers (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Implications for research
The review identified the need for research to assess the links be-
tween information provision, behaviour, and health outcomes.We
included trials which measured a behavioural outcome, for exam-
ple complying with the instructions for taking the medicine, be-
cause it is important to know whether people are taking prescribed
medications as directed. However, the use of behavioural change
as an outcome measure of the effectiveness of written information
about medicines can be doubted.We say this for two reasons. First,
the relationship between medicines information and behaviour is
probably far from direct, with many potential intervening vari-
ables. Second, some of the outcomes measured may not be rele-
vant to people taking medicines; compliance is an example, which
reflects the goals of those prescribing the medicines and not neces-
sarily the goals of those taking them. Similarly, drawing a possible
link between WMI and health outcomes may be difficult to as-
sess because of the indirect relationship, and numerous extraneous
variables to be considered. Still, an aim of information provision is
to improve health outcomes, albeit modified by knowledge, atti-
tudes and behaviours. Therefore there is a need for well-designed
research to examine this relationship.
Other research implications are as follows.
• First, future trials examining the effectiveness of WMI
should use consistent and validated outcome measures to enable
statistical comparison between studies.
• Second, future trials need to apply recognised standards to
their design, conduct and reporting.
• Third it may be worthwhile to define and apply an optimal
length of follow-up to evaluate the effectiveness of WMI over the
longer term. This is particularly important for medicines used
for chronic conditions.
• Fourth, there is a need for research to evaluate the effect of
applying best practice in the design of the leaflet on knowledge
and attitudes. In particular, there is a need to examine how
understandable the information in the leaflets actually is to users.
• Fifth, trials will benefit from greater input from qualitative
research, to help examine the role of WMI and the value that
people place on it.
• Finally, more research to evaluate internet-based medicines
information is needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arthur 1998
Methods Randomisation method: adequate (computer generated)
Concealment of allocation by remote access.
Baseline comparability: not reported.
Blinding: not reported.
8 to 12 weeks follow-up.
Participants UK. 80 adult patients (mean age 53 years; range 20 to 88) who had been prescribed or were already taking
one of six NSAIDs. 27% were male. They were excluded if their sight was impaired, they were unable to
read English, or if they had a history of inflammatory joint disease for more than five years
Interventions Intervention group: given patient information leaflet, and spoken explanation. The leaflet design and
content was based on evidence of readability, text size and style of layout (coloured card)
Control group: No written information provided, but received the spoken explanation alone which was
the same as the information in the leaflet. Leaflet was given at the end of the study
The information was for one of six NSAID (Non-Steroidal Anti Inflammatory Drugs); trade (generic)
names: Naprosyn (naproscen); Indocid (indomethacin); Brufen (ibuprofen); Relifex (nabumetone); Oru-
vail (ketoprofen); and Voltarol (diclofenac). This is used for treating inflammation of the joints, a chronic
condition. The information was on the nature of inflammatory joint disease, explanation of NSAID drug,
how drug works and should be taken, its administration in relation to most common side effects, side
effects themselves, the drug and pregnancy, and safe storage of the drug. Spoken information was on name
of NSAID, description on how to take the drug, its effects, side effects and to contact doctor in such an
event
Copy of leaflet available.
Leaflet was written in English language.
Information was provided by the author.
Outcomes Knowledge: number who correctly identified the six drugs as NSAIDs
Notes A third group received the leaflet only. This was not extracted as it would not isolate the effect of WMI
Additional demographic data, results for the individual groups, and information about concealment of
allocation were supplied by the author
Total withdrawal: 6/80 (8%)
Total loss to follow-up: 6/80 (8%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
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Baker 1991
Methods Randomisation method: not reported.
Baseline comparability: for age and sex.
Blinding: not reported.
2 weeks follow-up.
Participants UK. 125 adults (mean age 52 years) who were admitted to a Regional Cardiology Unit and were able to
read English. 63% were male. They were excluded if they were taking drugs for which there was no leaflet
Interventions Intervention group: patient information wallet comprising: (i) Introductory leaflet giving general advice
about the drug treatment; the importance of taking each dose as stated; seeking specific advice if pregnant;
driving as usual; drinking in moderation; destroying drugs not needed and asking if more information
is needed. (ii) Leaflets on specific prescribed individual drug stating what it does, precautions, and other
information. Spoken information also provided about the drug
Control group: No written information provided; spoken information only
The information was for 1 of 16 drugs covering four groups: glyceril trinitrate sublinguinal (GTS) tablets;
beta-blockers; warfarin; and digoxin; used for treating a cardiovascular (heart) condition, that is chronic.
The generic names of the drugs were: angiotensin converting enzyme inhibitators; amiodarone; beta-
androceptor antagonists; digoxin; diltiazem; dipyridamole; glyceril trinitrate; loop diruetics; nifedipine;
oral nitrates; potassium supplements; spironolactone; thiazide diruetics; verapamil; warfarin.
Provider of WMI not reported.
Copy of WMI available.
English language WMI.
Theory based - “Plain English Campaign” involved in WMI design
Outcomes Knowledge: recall information before leaving hospital to answer a number of questions about taking drug
(s): treatment purpose; action if miss dose; possible side effects; action re side effects; when to take drug;
how to take drug; whether you can drive; whether you can drink alcohol
Attitudinal: sufficient information felt to have been given; information felt to be clear and easy to under-
stand; information felt to be useful or extremely useful; reduced worry about drug treatment as a result
of specific information; felt information could be improved
Notes Total withdrawal: not reported
Total loss to follow-up: 24/125 (19%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Bergus 2002
Methods Randomisation method: adequate (random number table)
Baseline comparability: for sex, age and stroke familiarity.
Blinding: not reported.
Follow-up length unclear.
Participants USA. 217 adult patients (mean 39 years; range 18 to 70). 35% male. Excluded if non-English speaking
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Bergus 2002 (Continued)
Interventions Intervention group one: brochure with information about risks followed by benefits
Intervention group two: brochure with information about benefits followed by risks
No further spoken information was provided.
Included information was: risk of stroke = 2% over three years, reduced to 1% by use of aspirin. Risk
of GI side effects 40% with aspirin, two-fold increased risk of ulcers (but < 1/1,000 per year). Risk of
intracerebral haemorrhage 1/3,000 per year which is half that of non-aspirin users
The information was for aspirin, a generic drug with no trade name, used to decrease the risk of stroke in
carotid artery stenosis, a chronic condition.
Copy of WMI available.
English language WMI.
Theory based (information-order effect).
Outcomes Attitudinal: change in favourability of treatment rating
Notes Participants were also randomised to two surgical treatments for symptomatic carotid stenosis. These were
not extracted as they do not isolate the effect of WMI
Total withdrawal: not reported
Total loss to follow-up: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Clark 1972
Methods Randomisation method: not reported.
Baseline comparability: not reported.
Blinding: not reported.
1 to 3 days follow-up.
Participants USA. 45 adults (range 21 to 77 years) attending anticoagulant therapy clinic. 49% were male. Participants
had spent on average 11 years in education. Discharged on warfarin therapy. Included if they could
understand English and were able to distinguish small print
Interventions Intervention group one: “Programmed Instruction” booklet divided into five sections: action and indica-
tion for use of drug; laboratory testing; calculation of dosage; factors altering effect of drug; safety factors.
Provider of WMI not reported
Intervention group two: two page handout information sheet containing same essential information as
the programmed instruction booklet. Provider of WMI not reported
Control group: No written or spoken information provided.
The information was for warfarin, an anticoagulant (class of drug) used to thin blood. This is for the
treatment of a chronic condition. The generic and trade names for this drug were not reported.
Copy of partial WMI available.
Written in English.
Evidence based: content based on questionnaire results
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Clark 1972 (Continued)
Outcomes Knowledge: understanding of the use of the drug (possible score is 15)
Notes The information was for an anitcoagulant, warfarin.
Total withdrawal: 0/45 (0%)
Total loss to follow-up: 1/45 (2%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Desponds 1982
Methods Randomisation method: not reported.
Concealment of allocation by coded envelope.
Baseline comparability: for age, sex, first language, and education.
Outcome assessor only blinded.
2 to 3 day follow-up.
Participants Switzerland. 268 hospitalised adult patients (mean 60 years); 76% had previously received one of four
benzodiazepines (bromazepam, oxazepam, nitrazepam, flunitrazepam). 43% male. 86% French first lan-
guage; 18% had previously received spoken information about the drug; 59% had previously read the
Patient Information Leaflet (PIL); 92% considered the PIL important. Participants were excluded if they
had psychiatric or visual problems
Interventions Intervention received standardised WMI: the experimental PIL. Had more text than manufacturer PIL,
which was less medical. Included precaution and secondary effects, including addiction
Control received manufacturer WMI: more information on the therapeutic effect. No mention of action
to take in the event of accidental overdose or that the medicine required a prescription
The information was for one of four benzodiazepine drugs (generic names) bromazepam, oxazepam,
nitrazepam, flunitrazepam, used to relieve agitation, normally an acute condition
Outcomes Attitudinal:
Felt text: easy to understand; easy to read; interesting; judged to be complete; a lot of new information.
Knowledge:
Aggregated
% all correct, % partly correct, % missing, % wrong for questions about four drugs
Notes It is not clear from the reporting of the paper if additional spoken information was given or not. It is
possible that this was given, but it was not formally linked to the WMI provided
Total withdrawal: 0/222 (0%)
Total loss to follow-up: 0/222 (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
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Desponds 1982 (Continued)
Allocation concealment? Low risk A - Adequate
Dodds 1986
Methods Randomisation method: not reported.
Baseline comparability: for age, sex, drugs prescribed.
Blinding: only one of two outcome assessors blinded, hence consider to have been inadequate.
3 to 5 day follow-up.
Participants UK. 68 adults (mean age 28 years; range 16 to 81) discharged from hospital. 23% male. Included if
discharge prescription included up to four drugs and more than one antibiotic (more than five days) to
be self-administered
Interventions Intervention group: One of seven WMI on how to take drug, storage, what to do if miss dose, how it is
expected to help condition, and how to recognise side effects. A5 folded leaflet on coloured paper. Poorly
understood words and phrases were avoided. Readability and suitability of the WMI was assessed. Expert
consultation on layout of information. Question and answer format used to avoid the WMI appearing
dictatorial. Pictures used. Provider of WMI not reported
Control group: No written information provided.
The informationwas for one of eleven antibiotics (ampicillin, amoxycillin, cephalosporins, co-trimoxazole,
erythromicin, flucloxacillin, Magnapen, metronidazole, penicillin V, tertracycline, trimethropin), used to
treat bacterial infections, an acute condition. These are all generic drug names except Magnapen, which
is a trade name as it contains two antibiotics.
Copy of WMI available.
Theory-based.
English language
Outcomes Knowledge: median recall of information essential to correct drug taking
Behaviour: median patient behaviour questionnaire score for assessing actual drug taking
Behaviour: median patient compliance score (measured by tablet count and interview)
Notes If ’counselling’ about their medicines was requested, patients were withdrawn from the study.
The prescriber instructions were written, not spoken.
Total withdrawal: 5/68 (7%)
Total loss to follow-up: 7/68 (10%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Dolinsky 1983
Methods Randomisation method: not reported.
Baseline comparability: not reported.
Blinding: not reported.
Length of follow-up unclear.
Participants USA. 271 adults in receipt of prescription for either study drug from one of four outpatient clinics, one
community pharmacy, or one clinic, from a range of educational and occupational backgrounds
Interventions Intervention group 1: WMI sheet providing information on how to take the medicine, in the read-
organise-attend format, using underlining and shorter paragraphs than intervention group 2. Provider of
WMI not reported
Intervention group 2: WMI sheet with the same information as above, in the easy-to-read format, using
information that was ’readable’. Provider of WMI not reported
Control group: No written or spoken information provided.
The information was for a drug (generic name) methyldopa, used to treat high blood pressure, (a chronic
condition); or a drug (generic name) ampicillin, used to treat bacterial infections (an acute condition).
Copy of WMI available.
English language.
Theory based.
Outcomes Knowledge: correct recognition of drug information for either study drug.
Behaviour: correct application of drug information for either study drug
Notes This may have been a one day trial, which would change our judgement of numbers lost to follow-up and
withdrawal, but we could not ascertain this
Total withdrawal: 0/271 (0%)
Total loss to follow-up: 0/271 (0%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Gibbs 1989
Methods Randomisation method: Cluster randomisation of four towns.
Baseline comparability: for age and sex.
Blinding: not reported.
12 weeks follow-up.
Participants UK. 719 adults (over 16 years). 36% male from a small town attending a GP surgery and currently
prescribed one of the study drugs
Interventions Intervention: two sided WMI based on evidence. On the front was a short summary and on the back
greater detail was provided explaining the actions of the drug; what to do before, when and after taking
the drug; and storage of the drug. Cartoon icons were used. WMI was issued by GP during consultation
or by pharmacist during dispensing
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Gibbs 1989 (Continued)
Control: No written information provided.
GPs and pharmacists were requested not to go through the leaflet with the participants or give more
spoken information than was usual practice
The information was for the drugs (generic names) ß-blocker to lower blood pressure (a chronic condition)
, NSAID to treat inflammation of the joints (a chronic condition); or bronchodilator inhaler to treat
asthma (a chronic condition).
Copy of ß-blocker and bronchodilator inhaler WMIs available. NSAID WMI available in another pub-
lication.
English language.
Evidence based: had been previously piloted.
Outcomes Knowledge: overall patient knowledge re medicines for 9 questions (aggregated over all study drugs): name
medicine; therapy purpose; when to take it; take with fluid; take with food; action if miss dose; store out
of reach; safe disposal method; aware not to share medicines
Knowledge: overall patient awareness of side effects (aggregated over all study drugs)
Attitudinal: overall patient satisfaction response for information received (Aggregated over all study drugs)
; complete satisfaction; satisfaction; indifferent; dissatisfaction; complete dissatisfaction; don’t know
Notes Cluster randomised trial.
Total withdrawal: not reported
Total loss to follow-up: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Johnson 1986
Methods Randomisation method: not reported.
Baseline comparability: for age, sex, education, previous treatment.
Outcome assessor only blinded.
One month follow-up.
Participants USA. 34 adults (mean age 58 years) in a cardiac rehabilitation program taking a study drug (digoxin and/
or propranolol hydrochloride). 80% male, 82% completed high school, 41% completed college
Interventions Intervention group: one page WMI describing principal organ affected by drug, drug’s primary effects,
dosing regimen, and common side effects/toxicity. Provider of WMI not reported
Control group: No written information provided.
The information was for the drugs (generic names) igoxin and/or propranolol hydrochloride, used to treat
a variety of chronic conditions.
No copy of WMI available.
PresumeEnglish language WMI.
Not theory or evidence based.
Outcomes Knowledge: endpoint and change score of knowledge of drug.
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Johnson 1986 (Continued)
Notes Two participants in each group were taking both drugs and so were analysed for the outcome measure in
each group. This paper conducted two trials. We report only trial 2 as trial 1 did not use allocation.
It is not clear from the reporting of the paper if additional spoken information was given or not. It is
possible that this was given, but it was not formally linked to the WMI provided
Total withdrawal: not reported
Total loss to follow-up: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? High risk Inadequate
Knapp 2004
Methods Randomisation method: adequate.
No attempt was made to conceal allocation.
Baseline comparability: for age, sex, education, qualification.
No blinding.
Immediate follow-up.
Participants UK. 120 adults (mean age 63; range 35 to 74) attending cardiac rehabilitation following cardiac compli-
cations and were taking either of the study drugs. 63% male. 56% had no formal education qualification.
Excluded if first language was not English or could not read English
Interventions Intervention 1: written statement about one of two side effects in verbal form as suggested by EU regulation
(e.g. this is a rare side effect of the medicine)
Intervention 2: written statement about one of two side effects in numerical form (e.g. this side effect
occurs in 0.04% i.e. 4 out of 10,000 people who take this medicine)
No further spoken information was given.
Interventions were stratified by the drug that participants were taking (simvastatin or artovastatin)
The information was for the drugs (generic names) simvastatin or atorvastatin, used to lower high choles-
terol, a chronic condition.
Copy of WMI available.
English language WMI.
Intervention was not theory based.
Outcomes Knowledge: estimate of adverse events occurring; estimate of likelihood of occurrence
Aittitudinal: perceived risk to health; satisfaction with information; effect on decision to take medicines;
severity of side effects
Notes Patients had been taking the statin for variable periods and may have based responses on their own
experience as well as the information provided
Total withdrawal: 0/120 (0%)
Total loss to follow-up: 0/120 (0%)
Risk of bias
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Knapp 2004 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment? High risk Inadequate
Kumana 1988
Methods Randomisation method: not reported.
Baseline comparability for age, sex, diabetes duration.
Outcome assessor only blinded.
3 months follow-up.
Participants Hong Kong. 111 adults (mean age 56 years) with type 1 or type 2 diabetes attending a diabetic clinic.
37% male
Interventions Intervention group: 1-page hypoglycaemic WMI: stating need for drug, special instructions for taking
medication, what to do if you miss a dose, signs and symptoms of a hypoglycaemic reaction. Interviewed
before and after sheet was given. Provider of WMI not reported
Control group: No written information provided.
The information was for a hypoglycaemic agent, used to treat diabetes, a chronic condition. No generic
or trade name was reported.
Copy of WMI available.
English language on 1 side.
Chinese language on 1 side.
Not theory or evidence based.
3 months follow-up.
Outcomes Knowledge: endpoint and difference in patient knowledge on 10 questions
Notes It is not clear from the reporting of the paper if additional spoken information was given or not. It is
possible that this was given, but it was not formally linked to the WMI provided
Total withdrawal: not reported
Total loss to follow-up: 4/111 (4%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Labor 1995
Methods Randomisation method: not reported.
Baseline comparability: for age, sex, education, previous treatment.
Outcome assessor only blinded.
One day follow-up.
Participants USA. 150 adult patrons (mean age 43) from a University medical clinic. 45% had a college degree
Interventions Intervention 1: PIL: simple wording and 2 topic scope
Intervention 2: PIL: simple wording and 12 topic scope
Intervention 3: PIL: patient normal wording and 7 topic scope
Intervention 4: PIL: professional wording and 2 topic scope
Intervention 5: PIL: professional wording and 12 topic scope
No further spoken information was given.
Information = complexity of wording (simple, patient normal, professional). Scope = amount of infor-
mation about study drug (2, 7, 12 items).
The information was for an antihistamine, (trade name Seldane), used to treat allergic reactions, which is
an acute condition.
Partial copy of WMI available.
English language.
Leaflets were evidence-based: revised in a pilot study, and using Flesch reading levels test
Outcomes Attitudinal: topics judged ’about right’; complexity judged ’about right’; judgemental component; emo-
tional component; evaulative component
Notes Total withdrawal: 56/150 (37%)
Total loss to follow-up: 62/150 (41%)
Data are taken from Table 8, p1325.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Little 1998
Methods Randomisation method: adequate (random numbers table).
Baseline comparability: for age, education.
Outcome assessor only blinded.
Three month follow-up.
Participants UK. 636 women (mean age 27; range 21 to 31 years) attending a check-up appointment for repeat
prescription of combined pill. Excluded if younger than 17 years, unable to complete questionnaire, or if
first consultation for contraceptive pill
Interventions Intervention 1: evidence-based summary leaflet the size of a credit card containing a summary of the rules
of the contraceptive pill: aggregated over those receiving and not receiving questions
Intervention 2: Family Planning Association leaflet given with no explanation, but endorsed by the
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Little 1998 (Continued)
healthcare professional: aggregated over those receiving and not receiving questions
Control group: a blank leaflet.
The information was for an oral contraceptive pill (a drug group), for chronic use to prevent pregnancy.
No generic or trade name was reported.
Copy of WMI available.
Theory-based.
English language
Outcomes Knowledge: patient knowledge (getting all questions correct)
Notes Aggregated over those receiving and not receiving questions for each intervention. Missing data and data
about the trial conduct was received from author.
It is not clear from the reporting of the paper if additional spoken information was given or not. It is
possible that this was given, but it was not formally linked to the WMI provided
Total withdrawal: not reported
Total loss to follow-up: 99/636 (16%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk Adequate
McBean 1982
Methods Randomisation method: not reported.
Baseline comparability: for social demographic characteristics (not specified).
Blinded outcome assessment.
Three weeks follow-up.
Participants Canada. Chronically ill adults in receipt of a prescription for a cardiovascular drug, anti-inflammatory
drug, or cimetidine
Interventions Intervention: WMI only dispensed by pharmacist researcher
Control: pharmacy control receiving no written information
No further spoken information was given.
The information was for a cardiovascular drug (a drug group) used in chronic conditions; an anti-
inflammatory drug used in chronic conditions; or cimetidine, used to lower acid in the stomach, a chronic
condition.
WMI copy not available.
Presume English language.
Not theory or evidence based 3 weeks follow-up.
Outcomes Knowledge: participant knowledge at follow-up (difference from baseline)
Knowledge: median satisfaction with information
Behaviour: long-term compliance
Behaviour: side effect reported at follow-up (difference from baseline)
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McBean 1982 (Continued)
Notes Trial originally had six groups. We only extracted and report data from the two groups which could isolate
the effects of WMI. The other four arms did not isolate the effect of WMI. These arms were: written
and spoken private information; written and spoken nonprivate information; a second control arm; and
written and spoken telephone information
Originally 155 participants were randomised to the six interventions, but it is not reported how many
were divided into each intervention
Total withdrawal: not reported
Total loss to follow-up: 41/155 (26%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Morris 1982
Methods Randomisation method: not reported.
Baseline comparability: for age, ethnicity, education, employment.
Blinding not reported.
Three months follow-up.
Participants USA. 249 adults (median age 52 years) with newly diagnosed (< 6 months) mild essential hypertension
(DBP = 95 to 110 mmHg, no target organ damage). 54% male; 56% black and 33% Spanish-American.
Median number of years of schooling = 10.1 years and 39% graduated from high school
Interventions Intervention: WMI with 6 panels, measuring 9.3 x 21.6cm with orange-shaded illustrations describing
the uses and side effects of thiazide drugs, which were grouped according to reason for occurrence. Specific
side effects were printed in bold. Provider of WMI not reported
Control: No written information provided
The information was for thiazide diuretic (a drug group), used to lower high blood pressure, a chronic
condition. No generic or trade name was reported.
No copy of WMI available.
Spanish or English language WMI.
Not theory or evidence based.
Outcomes Knowledge: mean number of side effects correctly named after 2nd follow-up (17* possible side effects)
Knowledge: mean number of side effects incorrectly named after 2nd follow-up (17* possible side effects)
Knowledge: mean number of health problems reported at 2nd follow-up (17* possible side effects)
* Only 10 problems were stated in the WMI
Notes Intervention aggregated over those receiving and not receiving follow-up interview immediately after or
one month after intervention.
The paper reports different endpoint denominators for the numbers in each group for the different
outcome measures (knowledge and behaviour).
It is not clear from the reporting of the paper if additional spoken information was given or not. It is
possible that this was given, but it was not formally linked to the WMI provided
Total withdrawal: not reported
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Morris 1982 (Continued)
Total loss to follow-up: 104/249 (42%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Peura 1993
Methods Randomisation method: not reported.
Baseline comparability: for age, sex.
Treatment provider only blinded.
Followed-up “a few days later”.
Participants Finland. 500 adults (older than 16 years) in receipt of first time prescription for an antibiotic and purchased
themselves. 27% male
Interventions Intervention: electronically produced WMI with information in short sentences - dosage instructions,
need for finishing course, when to take drug, how to take drug, and mild side effects. Spoken information
also given. WMI provided by pharmacist
Control: No written information provided. Spoken information given from pharmacists alone
The information was for common antibiotics, a drug group; (trade names) Penicillin, Cephalophorins,
Erythromicin, Tetra-cycline, and Sulpha-Trimethroprim, prescribed in primary care, and used to treat
acute bacterial infections.
Copy of WMI available.
Presumably Finnish language WMI.
Not theory or evidence based.
Outcomes Knowledge: participants know what to do if miss a dose
Knowledge: participants know tablet taken with water
Knowledge: participants know recommendations for drinking alcohol and medication
Knowledge: participants know can take sauna during medication
Knowledge: participants can name at least 1 correct side effect
Notes Total withdrawal: not reported
Total loss to follow-up: 87/500 (17%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Peveler 1999
Methods Randomisation method: adequate (block randomisation).
Concealment of allocation by opaque sealed envelopes.
Baseline comparability: not reported.
Outcome assessor only blinded.
12 weeks follow-up.
Participants United Kingdom. 213 adults (mean age 45 years; range 21 to 83) attending GP for anti-depressant
treatment. 27%male. Excluded if in previous receipt of study drug (less than 3months), if contraindication
(concurrent medical condition), or if at risk of committing suicide
Interventions Intervention: EU directive based WMI about unwanted drug effects, and what to do in the event of a
missed dose, distributed by a nurse, aggregated over those receiving or not receiving counselling
Control : No written information provided, aggregated over those receiving or not receiving counselling
The information was for the drugs (generic names) dothiepin and amitriptyline, drugs used to treat
depression, which can be a chronic condition.
Copy of WMI available (from author).
English language WMI.
Not theory or evidence based.
12 weeks follow up.
Outcomes Behaviour: reported continuation of treatment at 6 months (checked against MEMS device recording
when tablet container was opened for dosing event)
Notes This was originally a factorial design trial. We have aggregated intervention one and intervention two over
the other (non-relevant intervention) counselling (provided by a nurse) and no counselling. Attention
control arm not included as it would not isolate the effect of WMI
Total withdrawal: Not reported
Total loss to follow-up: 9/213 (4%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Pope 1998
Methods Randomisation method: adequate (coin toss).
Baseline comparability: mean age, sex, duration taking NSAID, missed dose frequency.
Outcome assessor only blinded.
111 days follow-up.
Participants Canada. 72 adults (mean age 48; range 35 to 62) attending a rheumatology follow-up clinic. 31% male
Interventions Intervention: written drug information sheet providing information about the function of the drug, side
effects, contraindications, and advice on when to call the doctor. Spoken instructions also provided.
Provider of WMI not reported
Control: No written information provided. Spoken instructions only
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Pope 1998 (Continued)
The information was for an NSAID, a drug group used to reduce inflammation, a chronic condition. No
generic or trade name was reported.
Copy of WMI available.
Unclear what language(s) WMI was written in.
Not theory or evidence based.
Outcomes Knowledge: number of side effects listed for NSAIDs
Knowledge: number of correct side effects
Knowledge: correctly identify: don’t take NSAID on empty stomach
Knowledge: correctly identify: NSAIDS help with pain
Knowledge: correctly identify: don’t take ASA with NSAID
Knowledge: correctly identify: NSAID decrease inflammation
Knowledge: correctly identify: NSAID rarely cause a rash
Knowledge: correctly identify: NSAID can cause an ulcer
Knowledge: correctly identify: NSAID can cause GI bleed
Knowledge: correctly identify: call GP if heartburn occurs
Knowledge: correctly identify: call GP if black bowel movement
Notes Same WMI was given in Savas 2001. A third group received WMI. This was not extracted as it would
not isolate the effect of WMI
Total withdrawal: not reported
Total loss to follow-up: 1/72 (1%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? High risk Inadequate
Regner 1987
Methods Randomisation method: not reported.
Baseline comparability: not reported.
Blinding: not reported.
17 days follow-up.
Participants USA. 48 adults attending one of three outpatient clinics for a cardiac problem and presenting a new or
refill prescription
Interventions Intervention: spoken and printed information. Printed leaflet endorsed by American Society of Hospital
Pharmacists, based on current patient education material. Provider of WMI not reported
Control: No written information provided. Spoken instructions given
The information was for a drug (generic name) digoxin, used to treat a cardiac condition which is chronic.
WMI not available.
WMI presumably written in English.
Not theory or evidence based.
Outcomes Knowledge: recognition of side effects caused by the drug
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Regner 1987 (Continued)
Notes A 3rd group received WMI alone. This was not extracted as it would not isolate the effect of WMI
Total withdrawal: not reported
Total loss to follow-up: 14/48 (29%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Robinson 1986
Methods Randomisation method: not reported.
Baseline comparability: not reported.
Blinding: not reported.
2 weeks follow-up.
Participants USA. 100 voluntary participants who were residents in a psychiatric hospital and identified by their
treatment teams as ready for discharge to aftercare
Interventions Intervention: 1 to 2 page presumably English language medication information sheet (not available);
specific to the class(es) of medication on which they were being discharged and standard education
Control: No written information provided. Spoken information given
The information was for drugs (not reported) for treating mental health problems, that is a chronic
condition.
WMI presumably written in English.
Copy of WMI not available.
Not theory based.
Outcomes Knowledge: mean number of five questions answered correctly
Behaviour: post-discharge drug compliance
Notes A further 50 participants were recruited and randomised to receive the WMI which was reviewed with
a student nurse or psychology intern. This arm was excluded as it would not isolate the effect of WMI.
The differences in the number of participants measured for the knowledge and adherence outcomes was
due to them being measured at different points in time, at which point several had dropped out
Total withdrawal: not reported
Total loss to follow-up: 68/100 (68%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Savas 2001
Methods Randomisation method: adequate (random number table)
Baseline comparability for age and sex.
Blinding: not reported.
7 to 10 days follow-up.
Participants Turkey. 70 adults (mean age 50 years; range 28 to 73) attending outpatient clinic and prescribed NSAID
(> 3 per year)
Interventions Intervention: WMI + spoken information. WMI was presented using the active voice and short sentence
(8 to 10 words), and based on standard rules for written patient education material. Information on
benefits, side effects (with examples), advice to contact GP, warning not to take ’blood thinning drugs
with NSAID, when to stop drugs, rare side effects (with examples), warning not to take on an empty
stomach, and to contact rheumatologist for further information. Provider of WMI not reported
Control: No written information provided. Spoken information providing the same as information as the
leaflet given
The information was for a NSAID (a drug group) used to reduce inflammation, a chronic condition. No
generic or trade name was reported.
Copy of WMI available.
WMI presumably written in Turkish.
Not theory or evidence based.
Outcomes Knowledge: number of correct answers in 8-item questionnaire
Notes Same WMI was given in Pope 1998. A third arm received a PIL only and was not extracted as it was
irrelevant to this review because it did not isolate the effect of WMI
Total withdrawal: 9/70 (13%)
Total loss to follow-up: 9/70 (13%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Strydom 2001a
Methods Randomisation method: adequate (random number table)
Baseline comparability for age, sex, level of IQ and reading ability.
Outcome assessor only blinded.
5 weeks follow-up.
Participants UK. 57 adults (median age 36 years), 63% male, with mild-to-moderate learning difficulties and taking
psychiatric medication(s). Excluded people with severe and profound learning disabilities
Interventions Intervention: WMI + spoken information. WMI contained high quality medication information written
simply in large script according to readability guidelines, and illustrated with pictures. WMI provided by
a clinician
Control: No written information provided. Spoken information given by nurse or psychiatrist.
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Strydom 2001a (Continued)
WMI not available; presumably written in English.
The information was for one of eight drugs used to treat mental health problems, that is a chronic
condition. The generic and trade names for the drugs were not reported
Outcomes Knowledge: participant knowledge at 5 week follow-up
Notes Four treatment providers ignored the allocation system and their patients were subsequently withdrawn.
Missing data was received from author.
Total withdrawal: 5/56 (9%)
Total loss to follow-up: 6/56 (11%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
van Haecht 1991
Methods Randomisation method: adequate (random number table)
Baseline comparability: not reported.
Outcome assessor only blinded.
Length of follow-up unclear: outcome assessors enrolled for 6 months
Participants Belgium. 366 adults (mean age 38 years; range 14 to 82) with varying levels of school education, attending
GP surgery and receiving NSAID treatment for pain. 55% male. 50% ’low’, 32% ’middle’ and 18%
’higher’ level of education. Excluded if less 14 years old, pregnant, or if NSAID contraindicated
Interventions Intervention one: experimental PIL: explicit headings, lay terminology, simple syntax, with improved
readability (type size 9)
Intervention two: traditional insert: identical to PIL in every way, bar the specific characteristics above
The information was for a drug (generic name) pirprofen, which is an NSAID, used to reduce inflamma-
tion, and used here for acute muscle problems.
Copy of WMI not available.
Dutch language WMI.
Not theory based.
Length of follow-up unclear, but outcome assessors were enrolled for 6 months.
Intervention provided by GP
Outcomes Behaviour: read the PIL thoroughly:
Notes We could not include any other outcome measure as they reported only for those who had read the PIL,
and not by intervention
Total withdrawal: not reported
Total loss to follow-up: 49/366 (13%)
Risk of bias
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van Haecht 1991 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Vander Stichele 1992
Methods Randomisation method: adequate (block randomisation)
Baseline comparability for sex but not age.
Blinding not reported.
8 weeks follow-up.
Participants Belgium. 74 adults (age 52 to 70 years*) with mild-to-moderate essential hypertension (DBP: 90 to 115
mmHg), currently untreated or uncontrolled. 49% male, 100% white. Excluded if recently treated with
ß-blocker or ACE inhibitor, or if either treatment was contraindicated, or if suffered recent CVD.
* For those not lost to follow-up.
Interventions Intervention: WMI: information on indication for taking the drug, how to use and dosage, when not to
use, unwanted effects, special precautions, pregnancy and nursing a baby, interactions with other drugs,
driving and using machines, what to do in the event of an overdose, how to store drug. Treatment provider
was GP
Control: No written information provided
The information was for one of two drugs (trade names), Atenolol or Cisinopril, used to reduce high
blood pressure, a chronic condition. (WMI followed same design and information for each drug.) Copy
of WMI available. Dutch language WMI. Not theory or evidence based
Outcomes Behaviour: patient compliance (measured by MEMS device recording when tablet container was opened
for dosing event)
Notes Four treatment providers violated protocol and their six patients were withdrawn.
Six of the initial 74 participants were excluded from the trial: 3 were excluded because of flawed data
collection, and 3 because of protocol violation.
It is not clear from the reporting of the paper if additional spoken information was given or not. It is
possible that this was given, but it was not formally linked to the WMI provided
Total withdrawal: 18/68 (26%)
Total loss to follow-up: 28/68 (32%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Vesco 1990
Methods Randomisation method: not reported.
Baseline comparability: not reported.
Blinding: not reported.
8 days follow-up.
Participants France. 40 adults (mean age 43 years) with treatment naive asthma staying in a nursing home for respiratory
patients. 75% male
Interventions Intervention: package containing manufacturer’s instructions. Provider of WMI not reported
Control: No information.
The information was for a drug (generic name) slow-release theophylline, used to treat asthma, a chronic
condition.
Partial copy of WMI attached.
French language WMI (with English translation for report).
Not theory or evidence based
Outcomes Behaviour: endpoint theophylline blood levels
Behaviour: stopped taking medicine (measured by pill count)
Behaviour: side effects reported (symptom score per treatment day)
Notes Total withdrawal: 11/40 (28%)
Total loss to follow-up: 3/40 (8%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agunawela 1998 Cannot isolate effect of WMI alone
Al-Eidan 2002 Cannot examine effect of written information alone
Al-Rashad 2002 Not an RCT
Al-Saffar 2005 Inadequate randomisation
Anonymous 1999 Trial·examines·a readability formula
Ascione 1984 Does not present data for individual arms
Atherton-Naji 2005 Condition-based information
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(Continued)
Azrin 1998 Information was for different medicines
Barlow 1997 Condition-based information
Bernardini 2000 Not an RCT
Bernardini 2001 Trial·examines·a readability formula
Berry 1981 Unable to extract meaningful results
Berry 2002 Does not present data for individual arms
Berry 2004 Not patients
Berto 2000 Trial·examines·a readability formula
Bjorck Linne 2001 Cannot examine effect of written information alone
Chin-Quee 2006 Pictogram intervention
Clementsen 1992 Verbal information intervention
Clinite 1976 Not an RCT
Crawford 2003 Not an RCT
Crichton 1987 Not an RCT
Crilly 2005 Condition based information
Culbertson 1988 Not an RCT
Demiralay 2002 Condition-based information
Demiralay 2004 Condition-based information
Discenza 1992 Label study
Eaton 1980 Inadequate randomisation
Edworthy 1999 Trial·examines·a readability formula
Esposito 1995 Cannot examine effect of written information alone
Evans 1996 Not an RCT
Ferguson 1987 Label study
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(Continued)
Fincham 1995 Medication not widely available
Gardner 1990 Participants were not taking medicines
Halperin 1998 Not an RCT
Hannes 1991 Not an RCT
Hartzema 1999 Unable to extract meaningful results
Harvey 1991 Cannot examine effect of written information alone
Hayes 1996 Information about medicines not of primary focus
Hendler 2003 Verbal information intervention
Hill 2000 Verbal information intervention
Hill 2003 Verbal information intervention
Holcomb 2003 Trial·examines·a readability formula
Hussain 2003 Not an RCT
Hämeen-Anttila 2004 Pictogram intervention
Jacobs 1996 Not an RCT
Jones 2000 Study of illicit drug use
Kelloway 1993 Information about using a medicine appliance
Kirksey 2004 Trial·examines·a readability formula
Kirscht 1981 Condition-based information
Knapp 2005 Pictogram intervention
Krass 2002 Intervention is a method for rating leaflets
Laher 1981 Condition-based information
Lamb 1994 Verbal information intervention
Leal Hernández 2004 Information about a medical appliance
Ley 1976 Not an RCT
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(Continued)
Lirsac 1991 Information about a medical appliance
Little 2005 Condition-based information
Macfarlane 1997 Decision aids intervention
Macfarlane 2002 Decision aids intervention
Madoff 1996 Computer-based information intervention
Mainous 2000 Participants were not taking medicines
Mansoor 2003 Trial·examines·a readability formula
Mansoor 2006 Inadequate randomisation
Mansoor 2007 Inadequate randomisation
McCormack 2003 Condition-based information
Miquel 2000 Not patients
Morris, 1997 Not an RCT
Morrow 1998 Icon intervention
Mundt 2001 Condition-based information
Murphy 2002 Multicomponent complex intervention
Myers 1984 Cannot isolate effect of WMI alone
Myers 2004 Trial·examines·a readability formula
Neafsey 2002 Not incorporated into usual practice
Ngoh 1992 Icon intervention
Ngoh 1997 Icon intervention
Norrell 1979 Cannot examine effect of written information alone
O’Connell 1995 Trial·examines·a readability formula
Oldman 2004 Medicine is anaesthetic
Pander Maat 1996 Inadequate randomisation
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(Continued)
Quaid 1990 Evaluation of spoken information by health professional
Rabol 2002 Not an RCT
Rollins 2005 WMI is for different medicines
Ronmark 2005 Information about a medical appliance
Ruck 1990 Participants were not taking medicines
Russell 1979 Communication study
Sands 1984 Not an RCT
Sansgiry 2001 Examines information processing
Satterwhite 1980 Unable to extract meaningful results
Saunders 1991 Written reminders
Savage 2003 Information about a medical appliance
Schaffer 2004 Condition-based information
Segador 2005 Not WMI - reminder to take medicines
Smith 1986 Cannot examine effect of written information alone
Smith 1995 Not an RCT
Smith 1998 Trial·examines·a readability formula
Stratton 1984 Trial·examines·a readability formula
Sukkari 2001 Trial·examines·a readability formula
Suppatiporn 2005 Condition-based information
Swanson 1990 Trial·examines·a readability formula
Sweileh 2004 Unable to extract meaningful results
Temple 1997 Not an RCT
Thomas 1983 Trial·examines·a readability formula
Thomas 1998 Trial·examines·a readability formula
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(Continued)
Thompson 1988 Not written medicines information
Troller 1989 Not an RCT
Tymchuk 1990 Trial·examines·a readability formula
Udkow 1979 Not an RCT
van Haecht 1990 Not an RCT
Vivian 1980 Trial·examines·a readability formula
Webb 2001 Condition-based information
Webber 2001 Condition-based information
Whatley 2002 Provided hypothetical information
Whiteside 1983 Not written medicines information
Winkler 1981 Unable to extract meaningful results
Wise 1986 Condition-based information
Wiseman 1989 Not an RCT
Worsley 1989 Not an RCT
Young 2006a Participants were not taking medicines
Young 2006b Participants were not taking medicines
Zion 1989 Trial·examines·a readability formula
Zondag 2002 Not an RCT
Zweifler 1989 Condition-based information
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Trial outcome data
Trial WMI Characteristics Knowledge outcome Attitude outcome Behaviour outcome
Arthur 1998 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects













I: 22/38, n = 38 C: 14/
36, n = 36
(P < 0.01)
Naproxen
















I: 10/38, n = 38 C: 10/
36, n = 36
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Table 1. Trial outcome data (Continued)
(P < 0.01)
Brufen
I: 23/38, n = 38 C: 19/
36, n = 36
(P < 0.001)
Indocid




I: 25/38, n = 38 C: 19/
36, n = 36
(P < 0.001)
Oruvail
I: 7/38, n = 38 C: 7/36, n
= 36
(P = NS)
Baker 1991 * What this medicine is
and what it is used for
* How to take the drug
* Possible side effects






I: 43/49 (87.8%) C: 21/
52 (40.4%)
(P < 0.001)
action if miss dose




I: 34/49 (69.4%) C: 7/52
(13.5%)
(P < 0.001)
action re side effects
I: 26/49 (53.1%) C: 2/52
(3.8%)
(P < 0.001)
when to take drug




felt to have been given:
I: 36/49 (73.5%) C: 7/52
(13.5%)
(P < 0.001)
Information felt to be
clear and easy to under-
stand:
I: 44/49 (83.7%) C: 17/
52 (32.7%)
(P < 0.001)
Information felt to be
useful or extremely use-
ful:
I: 41/49 (83.7%) C: 17/
52 (32.7%)
(P < 0.001)
Felt information could be
improved:
I: 13/49 (26.5%) C: 33/
52 (63.5%)
(P < 0.001)
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Table 1. Trial outcome data (Continued)
how to take drug
I: 38/49 (77.6%) C: 35/
52 (67.3%)
(P = NS)
whether you can drive
I: 18/49 (36.7%) C: 14/
52 (26.9%)
(P = NS)
whether you can drink al-
cohol




drug treatment as a result
of specific information:
I: 26/49 (53.1%) C: 13/
52 (25.0%)
(P < 0.05)
Bergus 2002 * What this medicine is
and what it is used for
* Possible side effects




rating of favourability of
treatment:
I1: -5.2, I2: -10.9
(P = 0.02)
Clark 1972 * How to take the drug
* Partial copy of informa-
tion available
* Theory/evidence based
Understanding of the use
of the drug (possible score
is 15)
I1: 13.9 (SD 1.7) n = 15
I2: 11.1 (SD 3.3) n = 15
C: 10.3 (SD 3.6) n = 15
(P = 0.035 between I1 &
C)
(P = 0.008 between I1 &
I2)
Desponds 1982 * What this medicine is
and what it is used for
* How to take the drug
* Possible side effects




ber of questions about the
four drugs:
% all correct
I: 47.0% n = 114
C: 38.5% n = 108
% partly correct
I: 27.7% n = 114
C: 24.9% n = 108
% missing
I: 12.8% n = 114




C: 51/108 (P < 0.01)
easy to read
I: 106/114
C: 80/108 (P = NS)
interesting
I: 102/114
C: 84/108 (P = NS)
judged to be complete
I: 100/114
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Table 1. Trial outcome data (Continued)
% wrong
I: 12.5% n = 114
C: 20.5% n = 108
C: 79/108 (P < 0.05)
a lot of new information
I: 46/114
C: 23/108 (P < 0.05)
Dodds 1986 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
* Copy of information
available
* Theory/evidence based
Median recall of informa-
tion essential to correct
drug taking (max score =
10):





naire score for assessing
actual drug taking (max
score = 17):
I: 13/17, n = 31 C: 10/
17, n = 30
(P = 0.008)
Median patient compli-
ance score (measured by
tablet count and inter-
view) (max score = 27):
I: 21/27, n = 31 C: 15/
27, n = 30
(P = 0.0001)
Dolinsky 1983 * What this medicine is
and what it is used for
* How to take the drug
* Possible side effects





Ampicillin (Max score is
1.00):
I1: 0.87 (SD0.10) n = 19
I2: 0.85 (SD0.14) n = 18




I1: 0.77 (SD 0.2) n = 28
I2: 0.78 (SD 0.2) n = 29




Ampicillin (Max score is
9)
I1: 4.75 (SD2.02) n = 16
I2: 4.88 (SD2.18) n = 17




I1: 8.66 (SD2.78) n = 32
I2: 8.36 (SD2.87) n = 28
C: 8.40 (SD 2.66) n = 25
(P = NS)
Gibbs 1989 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
* Storage




edge re medicines for
9 questions (Aggregated
over all study drugs)
Name medicine:
I: 275/419 (65.6%) C:
220/300 (73.3%) (P < 0.
05)
Overall patient satisfac-
tion response for in-
formation received (Ag-
gregated over all study
drugs)
Complete satisfaction:
I: 294/419 (70.2%) C:
100/300 (33.3%)
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Table 1. Trial outcome data (Continued)
Therapy purpose:
I: 408/419 (97.4%) C:
284/300 (94.7%) (P =
NS)
When to take it:




I: 321/354 (90.7%) C:
175/200 (87.5%) (P =
NS)
Take with food:
I: 177/232 (76.3%) C:
67/100 (67.0%) (P =
NS)
Action if miss dose:
I: 223/419 (53.2%) C:
104/300 (34.7%) (P < 0.
001)
Store out of reach:
I: 361/419 (86.2%) C:
234/300 (78.0%) (P < 0.
005)
Safe disposal method:
I: 341/419 (81.4%) C:
245/300 (81.7%) (P =
NS)
Aware not to share
medicines:
I: 380/419 (90.7%) C:
251/300 (83.7%) (P < 0.
005)
Overall patient aware-
ness of side effects (Ag-
gregated over all study
drugs):
I: 160/419 (38.2%) C:
45/300 (15.0%) (P < 0.
001)
Satisfaction:
I: 107/419 (25.5%) C:
135/300 (45.0%)
Indifferent:
I: 9/419 (2.1%) C: 22/
300 (7.3%)
Dissatisfaction:




I: 0/419 (0%) C: 5/300
(1.7%)
Don’t know:
I: 6/419 (1.4%) C: 11/
300 (3.7%)
(P < 0.001)
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Table 1. Trial outcome data (Continued)
Johnson 1986 * What this medicine is
and what it is used for
* How to take the drug
* Possible side effects




of knowledge of drug:
I: 4.8 (1.3), n = 18 [+1.1
(1.7)*]
C: 4.5 (1.3), n = 20 [0 (0.
9)] (*P < 0.05)
Knapp 2004 * Possible side effects






I1: 18.0%, n = 30 I2: 2.
1%, n = 30
(95% CI of difference: 8.
2 to 23.5)
(P < 0.001)




I1: 3.3, n = 30 I2: 2.4, n
= 30
(95% CI of difference: 0.
3 to 1.5)
(P < 0.05)
Perceived risk to health:
I1: 3.4, n = 30 I2: 2.4, n
= 30






I1:34.2%, n = 30 I2:8.
1%, n = 30
(95% CI of difference:
15.1 to 37.0)
(P < 0.001)







I1: 3.3, n = 30 I2: 4.1, n
= 30
(95% CI of difference: 0.
08 to 1.6)
(P < 0.05)
Severity of side effect
I1: 3.7, n = 30 I2: 3.3, n
= 30
(95% CI of difference: -
0.2 to 1.1)
(P = NS)
Effect on decision to take
medicine
I1: 3.1, n = 30 I2: 2.5, n
= 30






I1: 3.4, n = 30 I2: 4.2, n
= 30
(95% CI of difference: -
0.3 to 1.6)
(P = NS)
Severity of side effect:
I1: 3.2, n = 30 I2: 2.8, n
= 30
(95% CI of difference: -
0.5 to 1.3)
(P = NS)
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Table 1. Trial outcome data (Continued)
I1:4.2, n = 30 I2:2.6, n =
30
(95% CI of difference: 0.
7 to 2.4)
(P < 0.001)
Perceived risk to health:
I1:3.2, n = 30 I2:2.3, n =
30
(95% CI of difference: 0.
4 to 1.8)
(P < 0.05)
Effect on decision to take
medicine:
I1: 3.8, n = 30 I2: 2.6, n
= 30
(95% CI of difference: 0.
7 to 2.2)
(P < 0.05)
Kumana 1988 * What this medicine is
and what it is used for
* How to take the drug
* Copy of information
available
Endpoint [change score]
in patient knowledge on
10 questions (Max score
= 10)
I: 5.8 (2.3), n = 56 [+1.3
(1.9)]
C: 6.3 (2.0), n = 51 [+1.
1 (1.6)]
(P = NS)
Labor 1995 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
























ish) re the information :
I1: 10.9, n = 16
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Table 1. Trial outcome data (Continued)
I2: 9.1, n = 19
I3: 12.2, n = 19
I4: 14.6, n = 17
I5: 13.6, n = 17
(P = 0.004)




irritated) re the informa-
tion:
I1: 12.0, n = 15
I2: 9.0, n = 19
I3: 10.9, n = 17
I4: 12.2, n = 17
I5: 12.2, n =17
(P = 0.24)
Summed scores for par-
ticipants “evaluation”
(useful, valuable, satisfy-
ing, beneficial and help-
ful) re the information:
I1: 16.4, n = 16
I2: 19.2, n = 18
I3: 18.9, n = 20
I4: 16.3, n = 17
I5: 17.5, n = 17
(P = 0.19)
Little 1998 * How to take the drug
* Copy of information
available
Patient knowledge (get-





I1 & C: (P < 0.05)
I1 & I2: (P = NS)
I2 & C: (P = NS)
McBean 1982 No copy of information
available.





I: 49.0% (+4) n = unclear




(Range 1 to 5) higher
score = greater satisfac-
tion:
I: 4 C: 3
Side effect reported at fol-
low-up (diff from base-
line):
I: 28.0% (+9.0) n = not
reported.
C: 20.0% (-4.0) n = not
reported.
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Table 1. Trial outcome data (Continued)
Long-term compliance:
I: 57.0% n = not re-
ported.
C: 55.0% n = not re-
ported.
Morris 1982 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
* Layout
Mean number of side ef-
fects correctly named af-
ter 2nd follow-up (17*
possible side effects):
I: 2.9, n = 102 C: 2.2, n
= 69
Mean number of side ef-
fects incorrectly named
after 2nd follow-up (17*
possible side effects):
I: 0.15, n = 102 C: 0.12,
n = 69
Mean number of health
problems reported at 2nd
follow-up (17* possible
side effects):
I: 4.1, n = 102, C: 3.6, n
= 53
* Only 10 problems were
stated in the WMI
Peura 1993 * What this medicine is
and what it is used for
* How to take the drug
* Possible side effects
* Copy of information
available
Participants know:
What to do if miss a dose
I: 194/218 (89%) C:
129/195 (66%)
(P < 0.001)
Tablet taken with water




for drinking alcohol and
medication
I: 139/218 (64%) C: 51/
195 (26%)
(P < 0.001)
Can take sauna during
medication
I: 198/218 (91%) C:
170/195 (87%)
(P = NS)
Name at least 1 correct
side effect
I: 183/218 (84%) C: 97/
195 (50%)
(P < 0.001)
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Table 1. Trial outcome data (Continued)
Peveler 1999 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
* Storage
* Copy of information
available
Patient reported contin-
uation of treatment at 3
months
I: 54 (50.9%), n = 106
C: 54 (50.5%), n = 107
(P=NS)
Pope 1998 * What this medicine is
and what it is used for
* Before taking the drug
* Possible side effects
* Copy of information
available
Number of side effects
listed for NSAIDs:
I: 0.6 (0.8), n = 34 C: 1.
2 (1.1), n = 37
(P = 0.02)
Number of correct side
effects:
I: 0.5 (0.6), n = 34 C: 0.
8 (0.8), n = 37
(P = 0.09)
Correctly identify:
Don’t take NSAID on
empty stomach
I: 29/30 (96.7%) C: 35/
35 (100%)
(P = 0.06)
NSAIDS help with pain:
I: 29/33 (87.9%) C: 23/
34 (67.6%)
(P = 0.05)
Don’t take ASA with
NSAID:





I: 28/33 (84.9%) C: 33/
36 (91.7%)
(P = 0.3)
NSAID rarely cause a
rash:
I: 13/33 (39.4%) C: 14/
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Table 1. Trial outcome data (Continued)
36 (38.9%)
(P = 0.9)
NSAID can cause an ul-
cer:
I: 29/34 (85.3%) C: 24/
33 (72.7%)
(P = 0.1)
NSAID can cause GI
bleed:
I: 16/33 (48.5%) C: 14/
36 (38.9%)
(P = 0.5)
Call GP if heartburn oc-
curs:
I: 16/32 (50.0%) C: 21/
37 (56.8%)
(P = 0.5)
Call GP if black bowel
movement:
I: 27/34 (79.4%) C: 29/
37 (78.4%)
(P = 0.9)
Regner 1987 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
* Storage
Recognition of side ef-
fects caused by the medi-
cation:
I: 1.8 (1.2), n = 15
C: 0.8 (0.8), n = 19
(P < 0.05)
Robinson 1986 No copy of the informa-
tion available.
Mean number of five
questions answered cor-
rectly
I: 4.38 (n = 50)
C: 3.20 (n = 50)
ANOVA with post-hoc





I: 4.32 (n = 16)
C: 3.88 (n = 16)
ANOVA with post-hoc
Scheffe test shows I andC
are significantly different
(P < 0.05)
Savas 2001 * What this medicine is
and what it is used for
* Before taking the drug
* Possible side effects
* Theory/evidence based
Number of correct an-
swers in 8q question-
naire:
I: 6.8 (0.9), n = 31 C: 5.
2 (1.5), n = 30
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Table 1. Trial outcome data (Continued)
(P = 0.0001)
Strydom 2001a * Theory/evidence based Patient knowledge at 5
weeks:
I: 6.8 (2.1), n = 24 C: 6.
9 (2.3), n = 26
95% CI for difference of
means: (-1.4 to 1.2)
(P = 0.89)
van Haecht 1991 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug




I1: 51/161 (31.7%) I2:
38/156 (24.3%)
(P = 0.15)
Vander Stichele 1992 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
* Storage
* Layout
* Copy of information
available
Patient compliance (mea-
sured by MEMS device
recording when tablet
container was opened for
dosing event):
I: 19/22 (86.4%) C: 17/
24 (70.8%)
(P = NS)
Vesco 1990 * What this medicine is
and what it is used for
* Before taking the drug
* How to take the drug
* Possible side effects
* Storage




I: 7.6 µgml-1 (3.13), n =
18












I: 0.7 (0.58), n = 18
C: 0.3 (0.31), n = 19
(P < 0.05)
I: Intervention group
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1. Drug Therapy/
2. exp Pharmaceutical Preparations/
3. exp Pharmaceutical Services/
4. exp Pharmacists/
5. exp Prescriptions, Drug/
6. exp Drugs, Non-Prescription/
7. exp Self medication/
8. prescription$1.ti,ab.
9. nonprescription$1.ti,ab.
10. over the counter.ti,ab.
11. (OTC not (organotin or ortnithine or oxytetracycline)).tw.
12. ((drug$1 or medication$) adj3 (information or instruction$ or education$ or advice or advise$)).tw.
13. or/1-12
14. Drug Labeling/




19. (drug$1 adj2 label?ing).tw.
20. pamphlet$1.ti,ab.
21. (medicines adj2 (information or instruction$ or advice or advise$ or educat$)).tw.
22. leaflet$1.ti,ab.
23. (patient$1 adj2 (information or instruction$ or advice or advise$ or educat$)).tw.
24. (consumer$1 adj2 (information or instruction$ or advice or advise$ or educat$)).tw.
25. (written adj2 (information or instruction$ or advice or advise$ or educat$)).tw.




30. (pack$ adj3 insert$1).tw.
31. (prescri$ adj2 information leaflet$1).tw.
32. or/14-31
33. 32 and 13
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Appendix 2. Data combination methodology
Analysis of outcomes will be based on intention-to-treat results where possible. A weighted mean treatment effect will be calculated
across trials using Cochrane RevMan software. The results will be expressed as Peto odds ratios and 95% confidence intervals (CIs) for
dichotomous outcomes, and weighted mean differences and 95% CIs for continuous outcomes. Sensitivity analysis will be performed
on the basis of methodological quality and to test for heterogeneity in the results.
WH A T ’ S N E W
Last assessed as up-to-date: 28 March 2007.
Date Event Description
14 September 2011 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 2, 2009
Date Event Description
28 April 2009 Amended Minor editing.
3 November 2008 Amended Converted to new review format.
12 May 2005 New citation required and major changes The protocol for this review was first published on issue 2 2000 of
The Cochrane Library by Knapp P, Raynor DK, Forster A, Henley
J.
The protocol was updated extensively on issue 3 2005 by Knapp
P, Raynor DK, Nicolson DJ, Blenkinsopp A, Grime J, Pollock K,
Spoor P, Gilbody S, Maule J, Dorer G, Dickinson D
C O N T R I B U T I O N S O F A U T H O R S
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DJN and PK wrote all drafts.
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D E C L A R A T I O N S O F I N T E R E S T
PK and DKR are directors of Luto Research Ltd, which provides patient information leaflet testing services to the pharmaceutical
industry. PK and DKR are authors of a trial included in this review (Knapp 2004); data for this trial were extracted by DJN and a 3rd
party (AB).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Health Technology Assessment, UK.
This funding paid for DJN’s salary as a research assistant on the HTA report, from which this review has arisen. It also contributed to
the salaries of a second research assistant and a research secretary on the same project.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• In the protocol we stated that the review would include randomised controlled trials (RCTs) in the first instance, with non-
randomised controlled trials, controlled before and after studies and interrupted time series studies to be considered in the absence of
RCTs. As a number of RCTs were identified for inclusion, we did not extend the selection criterion beyond RCTs, since these provide
a more robust level of evidence (see Types of studies).
• For the ’Types of Interventions’ selection criterion, we slightly revised the approach we had outlined in the protocol for this
review, and instead interpreted ’medicines information’ as information fulfilling at least one of the five European Union requirements
of mandatory leaflets supplied with medicines (EC 2004) (see Types of interventions).
• We added as a secondary outcome, changes in patients’ attitudes towards taking the medicine (see Types of outcome measures).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Drug Labeling; ∗Health Knowledge, Attitudes, Practice; ∗Nonprescription Drugs [adverse effects; therapeutic use]; ∗Prescription
Drugs [adverse effects; therapeutic use]; Patient Education as Topic [methods]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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